WO2014030749A1 - 網膜色素上皮細胞シートの製造方法 - Google Patents
網膜色素上皮細胞シートの製造方法 Download PDFInfo
- Publication number
- WO2014030749A1 WO2014030749A1 PCT/JP2013/072589 JP2013072589W WO2014030749A1 WO 2014030749 A1 WO2014030749 A1 WO 2014030749A1 JP 2013072589 W JP2013072589 W JP 2013072589W WO 2014030749 A1 WO2014030749 A1 WO 2014030749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- retinal pigment
- pigment epithelial
- cell layer
- Prior art date
Links
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 title claims abstract description 200
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 65
- 210000004027 cell Anatomy 0.000 claims abstract description 452
- 238000000034 method Methods 0.000 claims abstract description 98
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 95
- 210000000130 stem cell Anatomy 0.000 claims abstract description 62
- 210000002469 basement membrane Anatomy 0.000 claims abstract description 54
- 238000002054 transplantation Methods 0.000 claims abstract description 49
- 230000004069 differentiation Effects 0.000 claims abstract description 20
- 238000010030 laminating Methods 0.000 claims abstract description 17
- 230000001939 inductive effect Effects 0.000 claims abstract description 16
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 239000000512 collagen gel Substances 0.000 claims description 64
- 230000002792 vascular Effects 0.000 claims description 51
- 102000029816 Collagenase Human genes 0.000 claims description 45
- 108060005980 Collagenase Proteins 0.000 claims description 45
- 229960002424 collagenase Drugs 0.000 claims description 45
- 230000003511 endothelial effect Effects 0.000 claims description 44
- 210000001519 tissue Anatomy 0.000 claims description 26
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 8
- 238000010899 nucleation Methods 0.000 claims description 8
- 210000003566 hemangioblast Anatomy 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 abstract description 19
- 239000010410 layer Substances 0.000 description 137
- 102000008186 Collagen Human genes 0.000 description 61
- 108010035532 Collagen Proteins 0.000 description 61
- 229920001436 collagen Polymers 0.000 description 61
- 239000002609 medium Substances 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 37
- 241000282414 Homo sapiens Species 0.000 description 33
- 239000003550 marker Substances 0.000 description 32
- 230000033115 angiogenesis Effects 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 25
- 210000001525 retina Anatomy 0.000 description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
- 239000000523 sample Substances 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- 239000011259 mixed solution Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 238000001727 in vivo Methods 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000282693 Cercopithecidae Species 0.000 description 14
- 210000003161 choroid Anatomy 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000002919 epithelial cell Anatomy 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 239000000790 retinal pigment Substances 0.000 description 12
- 102000012422 Collagen Type I Human genes 0.000 description 11
- 108010022452 Collagen Type I Proteins 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 208000015122 neurodegenerative disease Diseases 0.000 description 11
- 230000002207 retinal effect Effects 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 108010042086 Collagen Type IV Proteins 0.000 description 9
- 102000004266 Collagen Type IV Human genes 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 208000002780 macular degeneration Diseases 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 7
- 108010085895 Laminin Proteins 0.000 description 7
- 102000007547 Laminin Human genes 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 7
- 238000005520 cutting process Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 7
- 229920000208 temperature-responsive polymer Polymers 0.000 description 7
- 210000002435 tendon Anatomy 0.000 description 7
- 206010003694 Atrophy Diseases 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
- 230000037444 atrophy Effects 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000000984 immunochemical effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001082 somatic cell Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 210000001578 tight junction Anatomy 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010046851 Uveitis Diseases 0.000 description 5
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
- 210000001775 bruch membrane Anatomy 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 238000012014 optical coherence tomography Methods 0.000 description 5
- 210000001778 pluripotent stem cell Anatomy 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
- 102000000591 Tight Junction Proteins Human genes 0.000 description 4
- 108010002321 Tight Junction Proteins Proteins 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 239000000823 artificial membrane Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000003475 lamination Methods 0.000 description 4
- 208000001491 myopia Diseases 0.000 description 4
- 230000004379 myopia Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 102100022794 Bestrophin-1 Human genes 0.000 description 3
- 108091016585 CD44 antigen Proteins 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 3
- 229920002971 Heparan sulfate Polymers 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 description 3
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
- WPWFMRDPTDEJJA-FAXVYDRBSA-N N-retinylidene-N-retinylethanolamine Chemical compound C=1C(\C=C\C=C(/C)\C=C\C=2C(CCCC=2C)(C)C)=CC=[N+](CCO)C=1\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C WPWFMRDPTDEJJA-FAXVYDRBSA-N 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 3
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000054 Syndecan-2 Proteins 0.000 description 3
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 3
- -1 acrylamide compound Chemical class 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000011557 critical solution Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 108010008217 nidogen Proteins 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 108091008695 photoreceptors Proteins 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 238000010165 Scheffé test Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 208000001309 degenerative myopia Diseases 0.000 description 2
- 230000004340 degenerative myopia Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000054350 human CHI3L1 Human genes 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000005155 neural progenitor cell Anatomy 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000001164 retinal progenitor cell Anatomy 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JMMZCWZIJXAGKW-UHFFFAOYSA-N 2-methylpent-2-ene Chemical compound CCC=C(C)C JMMZCWZIJXAGKW-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 description 1
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000193159 Hathewaya histolytica Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- OGKYMFFYOWUTKV-UHFFFAOYSA-N N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide Chemical compound C1=NC=C2C(S(=O)(=O)NCCN)=CC=C(Cl)C2=C1 OGKYMFFYOWUTKV-UHFFFAOYSA-N 0.000 description 1
- VUCPZDYKFDHFIK-UHFFFAOYSA-N N-propan-2-ylprop-2-enamide hydrate Chemical class CC(C)NC(=O)C=C.O VUCPZDYKFDHFIK-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000003940 Occludin Human genes 0.000 description 1
- 108090000304 Occludin Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 1
- 101150081664 PAX6 gene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 241001312734 Streptomyces parvulus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 101100068489 Vicia faba AGPC gene Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000003926 acrylamides Chemical class 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000001001 laser micro-dissection Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 101150087532 mitF gene Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000327 mueller cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001225 polyester resin Polymers 0.000 description 1
- 239000004645 polyester resin Substances 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000000768 retinal photoreceptor cell outer segment Anatomy 0.000 description 1
- 208000004644 retinal vein occlusion Diseases 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3808—Endothelial cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
- A61L27/3891—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types as distinct cell layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/28—Vascular endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Definitions
- the present invention relates to a method for producing a cell sheet, characterized by laminating a retinal pigment epithelial cell layer and a cell layer constituting a blood vessel after transplantation.
- the present invention also relates to a cell sheet for transplantation including a cell layer formed of retinal pigment epithelial cells, a basement membrane, and a layer of cells constituting a blood vessel after transplantation.
- retinal degenerative diseases by transplanting retinal pigment epithelial cells in a cell sheet state close to that in vivo.
- autologous tissue transplantation is performed in which a cell sheet obtained by cutting retinal pigment epithelial cells (as a layer with choroid) from retinal tissue of an age-related macular degeneration patient is transplanted into a damaged macular portion (for example, non-patented) References 1-3).
- the cell sheet derived from this patient tissue has an increased risk of invasiveness due to resection of the patient's retina, has a high incidence of complications, and has a rate of improvement in macular function and stability maintenance after transplantation. There was a problem such as low.
- retinal pigment epithelial cells can be cultured on artificial membranes or amniotic membranes to compensate for the lack of rigidity of very fragile monolayer epithelium as a method of using retinal pigment epithelial cells cultured in vitro, regardless of patient retina collection.
- a method of using the obtained cell sheet for transplantation is known.
- the artificial membrane is not suitable for transplantation because it differs in composition, properties, rigidity, etc. from the basement membrane produced by retinal pigment epithelial cells themselves in vivo and easily induces inflammation and associated rejection.
- the present inventors have reported a method of easily creating a cell sheet composed of retinal pigment epithelial cells cultured in vitro and a basement membrane produced by the cells themselves (for example, Patent Documents). 1). Since the cell sheet obtained by this method is accompanied by a basement membrane having the same components as those of a living body, it is easy to engraft, has rigidity, has excellent handleability, and is suitable for transplantation treatment.
- the retinal pigment epithelium disorder may be accompanied by choroid fibrosis and atrophy, lack of choroidal capillaries, and may be unable to supply nutrients to the retinal pigment epithelium and photoreceptor cells.
- transplanting a sheet of retinal pigment epithelial cells with a basement membrane lacks choroidal capillaries, so that nutrition and oxygen are not sufficiently supplied to the retinal pigment epithelium after transplantation.
- the obtained cells cannot sufficiently exert their functions in vivo and it is difficult to obtain the original therapeutic effect.
- Patent Document 2 reports that bone marrow-derived endothelial progenitor cells injected into the vitreous body are localized in the retinal astrocytes and incorporated into the vasculature to form normal retinal blood vessels.
- choroidal blood vessels that protect retinal pigment epithelial cells and photoreceptors that are also isolated in position.
- the object of the present invention is to develop a new method for producing a retinal pigment epithelial cell sheet in a simple and stable manner without using an artificial membrane.
- Another object of the present invention is to provide a retinal pigment epithelial cell sheet for transplantation having a high engraftment rate and excellent functionality even for patients with diseases such as severe uveitis.
- the present inventors have developed a method for producing a cell sheet, comprising laminating a retinal pigment epithelial cell layer and cells having the ability to form blood vessels after transplantation. Since the cell sheet obtained by such a method includes both a retinal pigment epithelial cell layer and an angiogenic cell layer, when transplanted to a patient, it not only reconstructs retinal tissue but also reconstructs the choroid through angiogenesis. Therefore, the present inventors have found that it is useful for the treatment of retina choroidal degenerative diseases, particularly retinal degenerative diseases accompanied by choroidal disorders.
- the resulting retinal pigment epithelial cell layer is formed between the collagen gel and the retinal pigment epithelial cell sheet. It has the same ability to secrete cytokines and adherence between cells as retinal pigment epithelial cells in vivo, and the retinal pigment epithelial cell layer is retained while retaining the basement membrane by degrading the collagen gel with collagenase. It could be easily detached from the cell culture substrate. Further, the cells constituting the retinal pigment epithelial cell layer maintained the expression of the retinal pigment epithelial cell-specific marker.
- the present invention provides the following: [1] A method for producing a cell sheet comprising a retinal pigment epithelial cell layer and an angiogenic cell layer, comprising a step of laminating a retinal pigment epithelial cell layer and an angiogenic cell layer. [2] The production method according to [1], wherein the retinal pigment epithelial cell layer and the angiogenic cell layer are laminated so that the angiogenic cell layer contacts the basal plane of the retinal pigment epithelial cell layer.
- the angiogenic cell layer is composed of at least one cell selected from the group consisting of hemangioblasts, vascular endothelial progenitor cells, and vascular endothelial cells.
- the angiogenic cell layer is composed of a patient-derived tissue or cell to be transplanted with a cell sheet, or a donor-derived cell in which the HLA type is compatible with the patient.
- the retinal pigment epithelial cell layer is a cell sheet produced by a method comprising the following steps: (1) a step of seeding and culturing retinal pigment epithelial cells on a collagen gel to form a cell sheet composed of retinal pigment epithelial cells; (2) A step of decomposing a collagen gel with collagenase and peeling a cell sheet composed of retinal pigment epithelial cells.
- the retinal pigment epithelial cells are cells obtained by inducing differentiation of ES cells, iPS cells or progenitor cells.
- a cell sheet for transplantation comprising a cell layer formed of retinal pigment epithelial cells obtained by inducing differentiation of stem cells or progenitor cells in vitro, a basement membrane secreted from the cells, and an angiogenic cell layer.
- the present invention it is possible to easily and stably produce a laminated sheet of retinal pigment epithelial cells having a vascular constituent cell layer that can compensate for deficient choroidal blood vessels in a living body and replenish oxygen and nutrients to the retina after transplantation.
- the cell sheet of the present invention is excellent in engraftment rate and functionality, it has a sufficient therapeutic effect only by retinal pigment epithelial cell transplantation, such as retina choroidal degenerative disease, particularly intense myopia and severe uveitis accompanied by retina choroidal atrophy. Since it is possible to treat severe retina-choroidal degenerative diseases that are difficult to obtain, it is extremely useful.
- FIG. 1 It is a figure which shows the immunohistochemical staining of the tissue section of the host which transplanted the cell sheet of this invention.
- A is a graph showing the number of angiogenesis of vascular endothelial progenitor cells per medium
- (B) is a graph showing the number of angiogenesis of vascular endothelial progenitor cells per medium when Matrigel is used. is there. It is a figure which shows the result of having tested the cytokine secretion ability of the retinal pigment epithelial cell sheet.
- the present invention provides a method for producing a cell sheet comprising the retinal pigment epithelial cell layer and the angiogenic cell layer (the production method of the present invention), comprising a step of laminating a retinal pigment epithelial cell layer and an angiogenic cell layer.
- the angiogenic cell layer in the present invention is composed of cells having angiogenic ability (angiogenic cells).
- angiogenic cells contained in the cell sheet reconstruct blood vessels (preferably choroidal blood vessels) at the transplant site. It is responsible for supplying oxygen and nutrients to retinal pigment epithelial cells. Therefore, the cell sheet obtained by the production method of the present invention can exhibit an excellent therapeutic effect by transplanting it to a choroid defect site of a patient with a retinal degenerative disease accompanied by a choroid defect.
- the angiogenic cell in the present invention is any cell as long as it is derived from a mammal (eg, human, monkey, mouse, rat, dog, cow, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc.) Cells derived from mammals may be used, but human-derived cells are preferred.
- a mammal eg, human, monkey, mouse, rat, dog, cow, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc.
- Cells derived from mammals may be used, but human-derived cells are preferred.
- angiogenic cells used in the present invention include hemangioblasts, vascular endothelial progenitor cells, and vascular endothelial cells.
- vascular endothelial progenitor cells and the like are preferable because they are likely to be incorporated into existing vascular networks in the process of angiogenesis in vivo after transplantation.
- the angiogenic cell layer may contain cells other than angiogenic cells and components other than cells, and may be composed of a cell population or tissue containing angiogenic cells. Normally, 70% or more (preferably 80% or more, more preferably 90% or more, most preferably 100%) of the cells constituting the angiogenic cell layer are angiogenic cells (preferably vascular endothelial precursor cells). .
- Vascular endothelial progenitor cells refer to cells that have the ability to differentiate into vascular endothelial cells and are committed to differentiation into vascular endothelial cells.
- expression patterns of a plurality of cell surface markers have been reported, and it is known that it is difficult to at least define them uniformly based on the expression patterns of cell surface markers.
- the expression patterns of vascular endothelial progenitor cell surface markers reported in the past include peripheral blood mononuclear cell-derived CD34 + vascular endothelial cells CD34 + , CD44 + , VEGFR2 + (KDR) (Science. 1997 Feb 14; 275 (5302).
- Cord blood mononuclear cell-derived vascular endothelial progenitor cells CD31 + , VEGFR2 + , eNOs + , CD105 + , CD34 +/ ⁇ , CD133 ⁇ , CD45 ⁇ , CD14 ⁇ , CD117 ⁇ (human endothelial colony formation) Cell (ECFCs (registered trademark), manufactured by Takara Bio Inc.)) and the like. These are thought to be caused by differences in tissues, differentiation stages, collection methods, and the like from which they are derived, but they are common in that they are cells that have the ability to differentiate into vascular endothelial cells.
- vascular endothelial progenitor cells are defined as “cells having the ability to differentiate into vascular endothelial cells and committed to differentiation into vascular endothelial cells”, and the expression pattern of the cell surface marker is The existence of multiple combinations is allowed.
- Vascular endothelial progenitor cells are known to be contained in yolk sac, peripheral blood, bone marrow, umbilical cord blood, and mononuclear cells thereof, and are prepared from these tissues or cells using a known isolation method.
- I can.
- an isolation method for example, a method of isolation using magnetic beads or FACS with the expression of cell surface markers such as CD34 and VEGF receptor 2 (KDR) as an index; a commercially available endothelial cell colony forming unit (CFU-ECs; Examples include a method using an endothelial cell colony-forming units (N Engl J Med. 2003; 348: 593-600).
- Specific examples of the method for producing peripheral blood mononuclear cells or bone marrow mononuclear cell-derived vascular endothelial progenitor cells include a medium for promoting vascular endothelial differentiation containing mononuclear cells isolated from peripheral blood or bone marrow by a conventional method.
- a method of recovering vascular endothelial progenitor cells as adherent cells using G-CSF; a method of separating and recovering vascular endothelial progenitor cells mobilized from bone marrow as CD34 positive cells from peripheral blood (Yakugaku Zashishi 2007) 125 (5) 841-845 etc. are known.
- Vascular endothelial progenitor cells can also be induced to differentiate from various cells, for example, a method of inducing differentiation through dedifferentiation from fibroblasts; vascular endothelial progenitor cells from pluripotent stem cells such as ES cells and iPS cells Methods for inducing differentiation (WO2008 / 056779, WO2009 / 035217, etc.) are known. These vascular endothelial progenitor cells can be used singly or in combination of a plurality of types. As the vascular endothelial progenitor cells in the present invention, a cell mixture containing other cells can also be used. For example, bone marrow cells containing vascular endothelial progenitor cells, peripheral blood mononuclear cells, bone marrow mononuclear cells and the like can be used as they are. .
- Vascular endothelial cells are separated from vascular tissues in vivo using a magnetic bead or FACS as an indicator of expression of cell surface markers such as CD31; the vascular endothelial progenitor cells are cultured in the presence of an inducing factor such as VEGF. It can be prepared by a known method such as a method for inducing differentiation.
- Vascular endothelial cells can also be induced to differentiate from various cells, for example, somatic stem cells such as mesenchymal stem cells and adipose tissue-derived stem cells; progenitor cells such as cardiac progenitor cells and neural progenitor cells; ES cells; It is known that differentiation can be induced from pluripotent stem cells such as iPS cells.
- HMVEC human microvascular endothelial cells
- HAVEC human umbilical vein endothelial cells
- HAOEC human aortic vascular endothelial cells
- Hemangioblasts are cells that are common ancestors of vascular endothelial progenitor cells and hematopoietic stem cells, and magnetic beads and FACS are used as indicators for expression of cell surface markers such as CD133, CD144, and CD45 from vascular tissues in vivo. It can prepare by well-known methods, such as the method of using and isolate
- angiogenic cell used in the present invention for example, a patient-derived tissue or cell to be transplanted with a cell sheet obtained by the production method of the present invention, or a donor-derived cell that matches the HLA type with the patient is used. Can do.
- angiogenic cells used in the present invention vascular endothelial precursor cells are particularly preferable.
- angiogenic cells suitable for autologous transplantation use for example, patient tissue, cells collected from this, iPS cell-derived cells established from patient somatic cells (patient iPS cells) are preferably used in that the burden on the patient is small. It is done.
- patient peripheral blood, mononuclear cells collected therefrom, patient peripheral blood mononuclear cell-derived cells, patient iPS cell-derived cells and the like are preferably used. These can be prepared by the above-described method using patient-derived cells.
- donor-derived cells that match the HLA type with the patient are preferably used in terms of suppressing rejection.
- the donor-derived cells that match the patient and the HLA type include donor tissue that matches the patient and the HLA type, cells collected from the tissue, iPS cells established from donor somatic cells that match the patient and the HLA type (HLA-compatible donor iPS cells) ) -Derived cells.
- Donor tissues and cells that are compatible with the HLA type can also be obtained from bone marrow banks or cell banks.
- cells having a trizygous (HLA-A, HLA-B, HLA-DR) homozygous type with low rejection with other HLA types are preferred as donor cells because they are compatible with many patients.
- the angiogenic cell layer is preferably laminated on the retinal pigment epithelial cell layer so that the angiogenic cell layer is in contact with the basal plane of the retinal pigment epithelial cell layer.
- An angiogenic cell layer may be laminated on at least a part of the retinal pigment epithelial cell layer.
- the density of the angiogenic cells with respect to the retinal pigment epithelial cell layer is not particularly limited, and can be appropriately selected and set in consideration of the disordered state of the choroid at the transplant site and the affinity with the existing vascular network.
- the density of angiogenic cells relative to the retinal pigment epithelial cell layer is, for example, 1 ⁇ 10 2 to 1 ⁇ . It is about 10 6 cells / cm 2 , preferably about 1 ⁇ 10 3 to 1 ⁇ 10 5 cells / cm 2 .
- an angiogenic cell layer having a high density of angiogenic cells is preferred.
- a known method can be used as a method of laminating a plurality of cell layers.
- Such methods include, for example, a method of laminating a plurality of sheet-like cell layers, a method of seeding cells constituting the other cell layer on one sheet-like cell layer, and a culture in a culture vessel A method of superposing the other sheet-like cell layer on the cell layer, a method of seeding cells constituting the other cell layer on one cell layer cultured in a culture vessel, and the like.
- the angiogenic cell layer is in contact with the basal plane of the retinal pigment epithelial cell layer.
- the angiogenic cell layer is brought into contact with the basal plane of the retinal pigment epithelial cell layer by superimposing a sheet-like retinal pigment epithelial cell layer on the angiogenic cell layer cultured in the culture vessel.
- the cell sheet obtained by laminating in the culture container can be used as it is.
- an angiogenic cell layer is seeded in a culture container using a medium and cultured to form an angiogenic cell layer in the culture container, and then separately formed retinal pigment.
- a medium By stacking the epithelial cell sheet on the angiogenic cell layer and sucking the medium, both cell layers can be laminated so that the angiogenic cell layer is in contact with the basal plane of the retinal pigment epithelial cell layer.
- the medium is not particularly limited as long as it is a composition capable of maintaining and culturing angiogenic cells and retinal pigment epithelial cells.
- both an angiogenic cell culture medium and a vascular endothelial precursor cell culture medium can be used.
- EGM-2 medium manufactured by Takara Bio Inc.
- EGM-2 medium manufactured by Takara Bio Inc.
- the cells adhere to at least the surface of the culture vessel and are allowed to stand for a time necessary for forming the angiogenic cell layer (for example, about 10 to 24 hours).
- a culture period of about 1 to 3 days may be provided.
- the production method of the present invention may further include a step (recovery step) of collecting a cell sheet in which a retinal pigment epithelial cell layer and an angiogenic cell layer are laminated.
- the method for collecting the cell sheet is not particularly limited as long as it is a method that can be collected while maintaining the sheet structure, and a known method can be used.
- a method for example, a method of peeling a cell sheet from a culture vessel by an enzyme treatment, a method using a cell non-adhesive culture vessel, a cell layer using a culture vessel surface-treated so as to be cell adhesive. Examples include a method of peeling a cell sheet formed by treatment with an enzyme or the like after lamination.
- the angiogenic cells adhere to the surface of the culture container during the laminating step, and the cells are fixed, thereby facilitating laminating the retinal pigment epithelial cell layer on the angiogenic cell layer.
- a method of peeling the cell sheet formed from the culture vessel after laminating the cell layer using the culture vessel surface-treated as described above is preferable.
- the cell sheet is peeled off by treatment with a temperature change.
- the temperature-responsive polymer refers to a polymer whose hydration power changes in a temperature-dependent manner.
- JP-A-2-21865 discloses a temperature-responsive polymer whose hydration power changes in a temperature range of 0 to 80 ° C.
- the monomer that can be used include a (meth) acrylamide compound, an N- (or N, N-di) alkyl-substituted (meth) acrylamide derivative, or a vinyl ether derivative. Two or more of these can be used.
- the temperature-responsive polymer is hydrated or dehydrated by changing the temperature, and the temperature range is 0 ° C. to 80 ° C., preferably 10 ° C. to 50 ° C., more preferably 20 ° C. to 45 ° C. .
- a suitable temperature-responsive polymer may include poly (N-isopropylacrylamide). Poly (N-isopropylacrylamide) is a polymer having a lower critical solution temperature at 31 ° C.
- cells eg, angiogenic cells, retinal pigment epithelial cells
- poly (N-isopropylacrylamide) hydrates and the surface of the culture vessel It becomes hydrophilic and becomes non-adhesive to cells.
- a temperature for example, 37 ° C.
- the lower critical solution temperature 31 ° C. in the case of poly (N-isopropylacrylamide)
- the cell sheet can be detached from the culture vessel and isolated without requiring enzyme treatment by adhering to the culture vessel and setting the temperature below the lower critical solution temperature (for example, 20 ° C.) in the recovery process. It is.
- Such culture vessels coated with a temperature-responsive polymer are described in JP-A-2-21865, JP-A-05-192138, JP-A-2008-220354, and the like.
- Such a culture vessel is commercially available as a temperature sensitive culture vessel (CellCell, UpCell (registered trademark)).
- CellCell UpCell (registered trademark)
- the angiogenic cells are adherently cultured in a temperature-responsive culture vessel coated with poly (N-isopropylacrylamide) at a temperature higher than the lower critical lysis temperature (31 ° C.) (eg, 37 ° C.).
- the lower critical lysis temperature 31 ° C.
- a retinal pigment epithelial cell layer (retinal pigment epithelial cell sheet) prepared separately while maintaining a temperature equal to or higher than the lower critical dissolution temperature (for example, 37 ° C.)
- the angiogenic cell layer is the base of the retinal pigment epithelial cell layer. Laminate on the angiogenic cell layer in contact with the surface.
- the culture is incubated below the lower critical lysis temperature (eg, 37 ° C.) for a time sufficient for the angiogenic cell layer and the retinal pigment epithelial cell layer to adhere
- the culture is incubated below the lower critical lysis temperature (eg, The formed cell sheet is peeled from the culture vessel by cooling to 20 ° C.
- the cooling and peeling are performed by, for example, sucking the culture medium, adding a culture medium having a temperature lower than the lower critical dissolution temperature (for example, 20 ° C.) to the culture container, and detaching the cell sheet from the culture container (for example, 30 minutes).
- the laminated cell sheet is collected.
- the medium is the same as that exemplified as a preferred embodiment of the lamination step. If the standing time after adding the cooling medium is too long, the cell sheet is difficult to peel off. Therefore, it is preferable to collect the sheet within one day after adding the medium.
- the production method of the present invention may also include a step of applying an angiogenesis treatment to the angiogenic cell layer.
- the angiogenesis treatment step may be either a pre-step or a post-step of the step of laminating the retinal pigment epithelial cell layer and the angiogenic cell layer.
- Angiogenesis treatment can be performed by a known method, for example, a method in which angiogenic cells are cultured in the presence of factors such as VEGF, IGF-1, PDGF, etc. in a collagen gel, and an angiogenic cell layer is defined as Matrigel. It can be applied by a known method for inducing tube formation such as a contact method. Since retinal pigment epithelial cells secrete VEGF, the culture supernatant of retinal pigment epithelial cells can also be used for angiogenesis.
- the angiogenic cell layer may have all the angiogenic cells constituting the vasculature, or only a part thereof.
- the angiogenic cell layer is preferably composed of blood vessels having a structure suitable for the environment of the transplant site in the living body.
- the transplanted angiogenic cells are spontaneously generated in vivo. In this process, it is considered that a functional vascular network is easily formed by connecting with existing blood vessels.
- angiogenesis treatment can be applied to the angiogenic cell layer to promote reconstruction of the vascular network based on the transplanted vasculature. preferable.
- the angiogenic cell layer includes cells other than angiogenic cells, for example, cells that support angiogenesis and angiogenesis such as hematopoietic stem cells, and vascular constituent cells other than vascular endothelial cells such as vascular smooth muscle cells and blood cells. Species or multiple species may be included.
- the angiogenic cell layer may further contain components other than cells, such as factors that promote angiogenesis.
- retinal pigment epithelial cell layer The retinal pigment epithelial cells used in the present invention may be primary cells collected directly from the eyeball, or may be obtained by substituting them for several generations.
- Primary retinal pigment epithelial cells can be isolated by known methods. For example, eyeball-derived retinal pigment epithelial cells can be isolated after cadaveric eyeball removal, and the eyeballs can be quickly divided at the equator and the vitreous and retina removed. If necessary, treat with collagenase, hyaluronidase, etc., scrape with a cell scraper or release cells from the Bruch membrane with trypsin or EDTA solution, collect the cells, and leave them in the culture medium. By inducing adhesion and proliferation, a necessary amount of cells can be proliferated and appropriately passaged by trypsin treatment or the like to ensure a sufficient number of cells.
- pluripotent stem cells such as embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) which are undifferentiated cells, stem cells containing somatic stem cells such as neural stem cells, or neural progenitor cells, It may be a cell obtained by inducing differentiation of progenitor cells including retinal progenitor cells.
- the ES cell may be an ES cell produced by nuclear reprogramming from a somatic cell.
- target cells may be prepared by inducing differentiation of recently reported induced pluripotent stem cells (iPS cells).
- An iPS cell can be prepared by introducing a specific nuclear reprogramming substance (nucleic acid, protein, low molecular weight compound, etc.) into a somatic cell, and is an artificial cell derived from a somatic cell having characteristics equivalent to those of an ES cell.
- a specific nuclear reprogramming substance nucleic acid, protein, low molecular weight compound, etc.
- Stem cells [Takahashi, K. And Yamanaka, S. , Cell, 126: 663-676 (2006); Takahashi, K .; Et al. , Cell, 131: 861-872 (2007)].
- Conditions / medium for differentiating the stem cells into target differentiated cells may be according to conventionally known conditions / medium, or may be appropriately set by those skilled in the art.
- a retinal pigment epithelial cell used in a cell sheet a stem cell or a progenitor cell, preferably a cell obtained by inducing differentiation of a pluripotent stem cell is used. It is preferable in that it can be prepared, and is particularly advantageous in that a relatively immature retinal pigment epithelial cell can be prepared and a cell sheet can be formed.
- the cell sheet prepared according to the present invention is used for transplantation, the cell sheet obtained by using somatic cells to be transplanted as a source of iPS cells is a cell sheet having no antigenicity to the subject. In view of this, the use of iPS cells is preferred.
- stem cells When stem cells are induced to differentiate, for example, human pluripotent stem cells such as ES cells and iPS cells, ES cells supplemented with Wnt antagonists such as Dkk-1 and CKI-7 and Nodal antagonists such as Lefty A and SB-431542 Culture in differentiation medium.
- Wnt antagonists such as Dkk-1 and CKI-7
- Nodal antagonists such as Lefty A and SB-431542 Culture in differentiation medium.
- Retinal progenitor cell markers Rx, Pax6, and Mitf are expressed by culturing for a certain period of time, and human retinal pigment epithelial cells are obtained by confirming cells with polymorphic morphology and pigment from morphological observation by optical microscope observation [Neuroscience Letters 2009 Jul 24 458 (3) 126-31, Journal of Cell Science 2009 Sep 1 122 (Pt 17) 3169-79].
- the retinal pigment epithelial cell layer in the present invention is composed of layers of retinal pigment epithelial cells arranged on a plane, and is configured as a cell sheet containing retinal pigment epithelial cells manufactured by a known method, for example. it can.
- a method for producing such a cell sheet for example, a method described in WO2011 / 142364 is known.
- a preferred embodiment of the cell sheet of the present invention is a cell sheet produced by a method in which the retinal pigment epithelial cell layer includes the following steps (hereinafter referred to as “collagen method”): (1) seeding and culturing retinal pigment epithelial cells on a collagen gel to form a cell sheet composed of retinal pigment epithelial cells; and (2) decomposing the collagen gel with collagenase and composing with retinal pigment epithelial cells. Peeling the applied cell sheet.
- the retinal pigment epithelial cells to be seeded include mammals (eg, human, monkey, mouse, rat, dog, cow, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc.) As long as it is a cell derived from any mammal, it may be a cell derived from any mammal, but is preferably a cell derived from a human.
- mammals eg, human, monkey, mouse, rat, dog, cow, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc.
- the collagen used in the collagen gel can be any collagen derived from mammals (eg, human, monkey, mouse, rat, dog, cow, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc.)
- mammals eg, human, monkey, mouse, rat, dog, cow, horse, pig, sheep, goat, cat, rabbit, hamster, guinea pig, etc.
- the type of collagen may be any type of collagen, but is preferably different from the collagen constituting the human basement membrane, specifically, collagen other than type IV collagen is preferred, Of these, it is preferable to use type I collagen.
- the collagen gel can be prepared by, for example, a conventionally known production method.
- the collagen gel is induced to form a collagen fiber network.
- Fibrous collagen has both strength and flexibility, and is easy to handle and good in maintaining cell proliferation and differentiation, and is preferred as a collagen gel used in the present invention.
- the collagen used in the present invention needs to be held on the surface of the gel without sinking into the gel layer when cells are seeded on the collagen gel.
- the collagen preferably has a gel strength necessary for cell growth, for example, collagen having a large amount of intermolecular crosslinking. Examples of such collagen include tendon-derived collagen.
- Collagen concentration of the collagen gel has a strength that allows retinal pigment epithelial cells to settle and proliferate, and can create a gel filled with solubility, easy-to-handle viscosity, etc. that can be easily degraded by collagenase. Any concentration may be used, but preferably 0.1% (W / V) to 0.5% (W / V), more preferably 0.2% (W / V). ⁇ 0.3% (W / V). When the collagen concentration of the collagen gel is less than 0.1% (W / V), the strength of the collagen gel is insufficient, and the retinal pigment epithelial cell colonization rate and cell growth rate are reduced. Further, when the collagen concentration of the collagen gel exceeds 0.5% (W / V), there is a concern that the collagenase treatment time for degrading the collagen gel becomes long and adversely affects the cells.
- the volume of the collagen gel mixed solution used for preparing the collagen gel is preferably about 100 ⁇ l to about 250 ⁇ l per unit area (cm 2 ), more preferably, although it depends on the culture area and shape of the culture substrate used for cell culture. Is about 150 ⁇ l to about 200 ⁇ l.
- the amount of the collagen gel mixed solution is too small, a thin collagen gel layer is formed due to the surface tension acting on the gel surface, and the cells directly contact the culture substrate as the retinal pigment epithelial cells are cultured. Therefore, when a cell sheet composed of retinal pigment epithelial cells is cut out, the sheet is likely to be damaged.
- a cell sheet composed of retinal pigment epithelial cells can be prepared by seeding and culturing the retinal pigment epithelial cells on a collagen gel as a cell culture substrate.
- the cell culture substrate in the present specification is not particularly limited as long as it is for cell culture.
- a culture vessel, a flask, a tissue culture flask, a dish, a petri dish, a tissue having a porous film such as a transwell Culture dishes, multi dishes, micro plates, micro well plates, multi plates, multi well plates, chamber slides, petri dishes, tubes, trays, culture bags, roller bottles, etc.
- a culture vessel having a porous membrane is preferable from the viewpoint of simplicity, and for example, a commercially available transwell is preferably used.
- Examples of the material for the cell culture substrate in the present specification include inorganic materials such as metal, glass, ceramic, and silicon, elastomers, and plastics (for example, polyester resin, polyethylene resin, polypropylene resin, ABS resin, nylon, acrylic resin, An organic material typified by a fluorine resin, a polycarbonate resin, a polyurethane resin, a methylpentene resin, a phenol resin, a melamine resin, an epoxy resin, or a vinyl chloride resin) can be given, but is not limited thereto.
- the number of retinal pigment epithelial cells to be seeded may be in any range as long as the cell density can form a cell sheet. However, if the cell density is too sparse, the shape of the cells is poor, the incubation time for the cells to reach a confluent state is long, and the time it takes for the cells to mature and become colored is also long. Even if it is too much, cell growth is similarly suppressed, and the culture time until reaching a confluent state tends to be long, and cells may die due to overcrowding. Accordingly, the seeded cell density is preferably about 4.5 ⁇ 10 4 cells / cm 2 to about 8.5 ⁇ 10 5 cells / cm 2 , more preferably about 8.5 ⁇ 10 4 cells. / Cm 2 to about 8.5 ⁇ 10 5 cells / cm 2 , most preferably about 4.5 ⁇ 10 5 cells / cm 2 .
- a monolayer cell population (cell sheet) composed of the retinal pigment epithelial cells can be formed.
- Any culture medium can be used without particular limitation as long as it is a cell culture medium usually used in the art.
- a basal medium as described in "Culture Technology Third Edition", page 581 can be used.
- serum such as fetal bovine serum
- various growth factors such as EGF, FGF, HGF, PDGF, etc.
- antibiotics amino acids, etc.
- the pH of the medium is preferably about 6 to about 8.
- the primary culture is usually performed at about 30 to about 40 ° C. for about 15 to about 60 hours until the retinal pigment epithelial cells become confluent.
- the secondary culture is performed for about 1 week to about 2 months while exchanging the medium, and the culture is performed until a cell sheet is formed while aeration and agitation are performed as necessary.
- Cells constituting the cell sheet obtained by such culture are maintained as retinal pigment epithelial cells. Whether the cells are maintained as retinal pigment epithelial cells can be confirmed by detecting BEST1, RPE65, MERTK, CRALBP, or the like as a specific differentiation marker.
- the collagen gel adhered to the cell sheet formed in the step (1) is decomposed with collagenase.
- a person skilled in the art can select an appropriate collagenase according to the type of collagen used in the preparation of the collagen gel.
- the collagenase used for the degradation of the collagen gel is not particularly limited as long as it has an activity capable of digesting the collagen gel, but it is difficult to degrade the collagen constituting the human basement membrane (for example, type IV collagen).
- a collagenase derived from a microorganism that is commercially available and is derived from Clostridium histolyticum or Streptomyces parvulus which is safe and has high enzyme activity can be used.
- the specific activity of collagenase used for collagen gel dissolution is preferably 0.1 U / mg or more. If the specific activity of collagenase is less than 0.1 U / mg, it takes too much time to dissolve the collagen gel or the gel may not be sufficiently dissolved.
- the range is more preferably 0.1 to 10,000 U / mg, still more preferably 1 to 3,000 U / mg.
- the method for causing collagenase to act on the collagen gel is not particularly limited.
- a collagenase solution prepared using a medium or a buffered isotonic solution as a solvent may be added to the medium, or a cell-attached collagen gel peeled from a cell culture dish may be immersed in the collagenase solution.
- the collagen gel layer can be exposed by recovering the insert and removing the membrane on the bottom surface of the insert, and the collagenase directly on the exposed collagen gel. It is preferable to immerse the solution.
- the time for dissolving the collagen gel with collagenase is not particularly limited. However, if the time for allowing collagenase to act is too long, cell functions such as adhesion ability and proliferation ability may decrease, which is not preferable.
- the time for performing collagenase lysis is usually 15 minutes to 60 minutes, although it is affected by the specific activity of collagenase, temperature, collagen gel shape, collagenase treatment method and the like.
- the collagenase treatment may be performed once or may be performed in multiple steps.
- the temperature during collagenase treatment of collagen gel in the collagen method is generally 10 ° C. or more lower than the in vivo temperature in cells (about 30 ° C. in humans), the fluidity of the cytoplasm decreases and the metabolic capacity decreases, and the temperature is 42 If the temperature is higher than 0 ° C., the protein may be denatured and the cell function may be lowered. In addition, the optimum temperature for collagenase is often 37 ° C., and the lysis time may be longer at temperatures below 10 ° C. It is preferable to set within a range of 42 ° C. More preferably, it is 30 to 40 ° C, and further preferably 36 to 38 ° C.
- the cell sheet is gradually detached from the gel and finally released into the collagenase solution.
- the cell sheet may be mechanically peeled from the remaining gel, or the cell sheet may be recovered after the gel is completely dissolved. Although the time until the cell sheet is collected is shortened by mechanically peeling, the cell sheet may be destroyed. Therefore, it is preferable to collect the cell sheet after the gel is completely dissolved.
- the cell sheet collected as described above can be used as it is in the laminating step with the angiogenic cell layer, but the residual collagenase may inhibit the adhesion to the angiogenic cell layer. It is preferable to wash with an isotonic solution.
- the temperature at the time of washing can be set according to collagenase dissolution treatment of collagen gel. In order to sufficiently remove residual collagenase, it is preferable to wash at least once with a medium or an isotonic solution having a buffer capacity.
- Cell sheets composed of retinal pigment epithelial cells obtained by the collagen method secrete cytokines peculiar to retinal pigment epithelial cells with the same polarity as in vivo, and transepithelial electricity serves as an indicator of tight junctions between cells.
- the resistance (TER) was increased in the same manner as in the living body, it has a cell layer barrier function similar to that in the living body.
- a cell sheet composed of retinal pigment epithelial cells having the same function as that in the living body can be obtained.
- the “basement membrane” is a membrane formed from components produced from retinal pigment epithelial cells, and includes a membrane containing at least a part of the basement membrane components (hereinafter referred to as “basement membrane of retinal pigment epithelial cells”). ”)").
- the basal membrane of retinal pigment epithelial cells in vivo exists in a thin film between the retinal pigment epithelial cell layer and the inner collagen layer constituting Bruch's membrane.
- Type IV collagen laminin, heparan sulfate proteoglycan (pearl can), nidogen It is an extracellular matrix which has a representative component.
- the Bruch's membrane is a thin membrane between the retinal pigment epithelial cell layer and the choroid, and is composed of five layers: a retinal pigment epithelial cell basement membrane, an inner collagen layer, an elastin layer, an outer collagen layer, and a choroidal capillary plate basement membrane.
- a cell sheet composed of a structure and composed of retinal pigment epithelial cells obtained by the collagen method includes a part of the Bruch's membrane structure (base membrane of retinal pigment epithelial cells).
- Tight junction formation can be confirmed by observing hexagonal closely-attached cell morphology and expression of occludin, ZO-1, etc. between cells by immunostaining. Formation of the basement membrane is confirmed by observing the expression on the cell surface of basement membrane markers such as laminin, heparan sulfate proteoglycan (pearlcan), nidogen, or type IV collagen by immunostaining, or by observation with a scanning electron microscope be able to.
- basement membrane markers such as laminin, heparan sulfate proteoglycan (pearlcan), nidogen, or type IV collagen by immunostaining, or by observation with a scanning electron microscope be able to.
- retinal pigment epithelial cells produce a basement membrane component when cultured on a culture dish, but are extremely difficult to detach as a retinal pigment epithelial cell sheet that can be detached from the culture dish and used.
- Pigment epithelial cells can be collected as a sheet.
- retinal pigment epithelial cells have a single-layer structure, if they are handled alone, the sheet structure collapses and becomes dissociated into cell units, making it extremely difficult to transplant as a sheet.
- a cell sheet composed of retinal pigment epithelial cells obtained by the collagen method has sufficient rigidity with a basement membrane, so that it is difficult to wrinkle when the sheet is collected, and the handling becomes extremely easy. Therefore, the lamination operation with the angiogenic cell layer can be performed smoothly.
- Bruch's membrane may also be damaged, but by using a retinal pigment epithelial cell sheet obtained by the collagen method as the retinal pigment epithelial cell layer in the production method of the present invention,
- the basement membrane of the cell sheet produced by the method supplements the damaged portion, whereby the cell sheet engraftment rate can be improved and the therapeutic effect can be expected.
- the production method of the present invention when a retinal pigment epithelial cell sheet obtained by the collagen method is used as a retinal pigment epithelial cell layer, the produced cell sheet is used for transplantation for diseases associated with basement membrane disorders. It is suitable as a sheet, and can be suitably used as a sheet for transplantation particularly targeting age-related macular degeneration.
- the collagen method may further include the following step (3).
- step (3) A step of confirming the presence or absence of a basement membrane on the contact surface of the peeled cell sheet with the collagen gel
- step (3) by confirming the presence or absence of a basement membrane in the cell sheet, it is possible to determine the formation of a cell sheet composed of a cell layer composed of retinal pigment epithelial cells and a basement membrane.
- the presence or absence of the basement membrane can be confirmed by the same method as the above-mentioned confirmation of the formation of the basement membrane, such as expression of a basement membrane marker or observation with a scanning electron microscope.
- the expression of the basement membrane marker may be confirmed at any location of the cell (eg, cytoplasm, cell membrane, nuclear membrane, etc.), but preferably the marker is expressed on the contact surface with the collagen gel Is targeted.
- the basement membrane marker includes a transcription product, translation product or degradation product of a gene specifically expressed in the basement membrane.
- genes include laminin, heparan sulfate proteoglycan (Perlecan), nidogen, and type IV collagen.
- laminin which is a main component of the basement membrane, type IV collagen, and the like are preferably used.
- a basement membrane marker derived from the cell sheet (or cell) peeled in step (2) eg, RNA, protein, degradation products thereof, etc.
- RNA, protein, degradation products thereof, etc. are not particularly limited.
- the expression of the basement membrane marker gene is contained in the RNA (eg, total RNA, mRNA) fraction prepared from the cells of the cell sheet detached in step (2). It can be examined by detecting the transcription product of the marker gene or by directly detecting the marker gene product in the cell without extracting RNA from the cell.
- RNA eg, total RNA, mRNA
- the RNA fraction can be prepared using a known method such as guanidine-CsCl ultracentrifugation or AGPC.
- an extraction kit eg, RNeasy Mini Kit; manufactured by QIAGEN, etc.
- high-purity total RNA can be prepared quickly and easily from a small amount of sample.
- a means for detecting the transcription product of the basement membrane marker gene in the RNA fraction for example, a method using hybridization (Northern blot, dot blot, DNA chip analysis, etc.) or PCR (RT-PCR, competitive PCR, real time) And the like using PCR.
- Quantitative PCR methods such as competitive PCR and real-time PCR can detect changes in the expression of a basement membrane marker gene from a small amount of sample quickly and easily with high quantitativeness.
- DNA chip analysis is preferable in that it can be improved and quantitativeness can be improved by selecting a detection method.
- the detection of a basement membrane marker gene can be performed using a nucleic acid (probe) that can hybridize with a transcription product of the gene.
- a nucleic acid include a nucleic acid that can hybridize with a transcription product of a basement membrane marker gene under highly stringent conditions.
- “High stringent conditions” means, for example, a hybridization reaction at 45 ° C. in 6 ⁇ SSC (sodium chloride / sodium citrate), followed by one at 65 ° C. in 0.2 ⁇ SSC / 0.1% SDS. Cleaning more than once.
- the nucleic acid may be DNA or RNA, or may be a DNA / RNA chimera.
- DNA is used.
- the nucleic acid used as the probe may be double-stranded or single-stranded. In the case of a double strand, it may be a double-stranded DNA, a double-stranded RNA or a DNA: RNA hybrid. In the case of a single strand, an antisense strand can be used.
- the length of the nucleic acid is not particularly limited as long as it can specifically hybridize with the target nucleic acid, and is, for example, about 15 bases or more, preferably about 30 bases or more.
- the nucleic acid is preferably labeled with a labeling agent in order to enable detection and quantification of the target nucleic acid.
- a radioisotope for example, an enzyme, a fluorescent substance, a luminescent substance, or the like is used.
- the radioisotope for example, [ 32 P], [ 3 H], [ 14 C] and the like are used.
- the enzyme those which are stable and have high specific activity are preferable.
- ⁇ -galactosidase, ⁇ -glucosidase, alkaline phosphatase, peroxidase, malate dehydrogenase and the like are used.
- the fluorescent substance for example, fluorescamine, fluorescein isothiocyanate and the like are used.
- luminescent substance for example, luminol, luminol derivatives, luciferin, lucigenin and the like are used.
- biotin- (strept) avidin can also be used for binding between the probe and the labeling agent.
- the RNA fraction prepared as described above is separated by gel electrophoresis, then transferred to a membrane such as nitrocellulose, nylon, polyvinylidene difluoride, and prepared as described above.
- a membrane such as nitrocellulose, nylon, polyvinylidene difluoride, and prepared as described above.
- Each of the basement membranes was measured by measuring the amount of label bound to the membrane for each band after hybridization in the above-mentioned “hyperstringent conditions” in a hybridization buffer containing the labeled probe.
- the expression level of the marker gene can be measured.
- dot blots the expression level of each marker gene is measured by subjecting the membrane on which the RNA fraction is spotted to the hybridization reaction in the same manner (respectively for each marker gene), and measuring the amount of label on the spot. be able to.
- cDNA in which an appropriate promoter such as T7 promoter is introduced is synthesized from the RNA fraction prepared as described above by reverse transcription, and further cRNA is synthesized using RNA polymerase (this)
- a labeled cRNA is obtained by using a mononucleotide labeled with biotin or the like as a substrate).
- the labeled cRNA is brought into contact with the above-described probe on which the probe is immobilized and subjected to a hybridization reaction, and the amount of label bound to each probe on the solid phase is measured to measure the expression level of each basement membrane marker gene. can do.
- This method is more advantageous in terms of rapidity and simplicity as the number of differentiation marker genes to be detected (and hence immobilized probes) increases.
- in situ hybridization can be used as the detection means.
- the cells instead of extracting RNA from the cells, the cells are fixed by treating the cells with a fixative, preferably a precipitation fixative such as acetone, or by incubating in a buffered formaldehyde solution for a short time. After fixation, the cells are embedded in paraffin to form a block, and a slice can be cut off and used as a sample. Well-prepared paraffin-embedded samples can be stored for many years at room temperature.
- the nucleic acid used as the probe the same nucleic acid as described above can be used.
- In situ hybridization is preferably used in the present invention in that the expression of a basement membrane marker can be directly confirmed on the contact surface of a cell with a collagen gel.
- the confirmation of the expression of the basement membrane marker gene in the detached cell sheet in the step (2) is performed by preparing a protein fraction from the cell sheet (or cell) and translating the marker gene contained in the fraction
- the product ie, marker protein
- the product can be detected, or can be examined by detecting the translation product of the marker gene directly in the cell sheet (or cell) without extracting the protein from the cell sheet (or cell) .
- Marker protein can be detected by immunoassay (eg, ELISA, FIA, RIA, Western blot, etc.) using antibodies against each protein, or a protein exhibiting measurable physiological activity such as an enzyme. In, the physiological activity can also be measured by measuring each marker protein using a known method.
- the marker protein can also be detected using mass spectrometry such as MALDI-TOF MS.
- mass spectrometry such as MALDI-TOF MS.
- the antibody with respect to each marker protein can be acquired according to the polyclonal antibody or monoclonal antibody preparation technique normally used by making this marker protein or this protein, or its partial peptide into a sensitizing antigen.
- a measurement system for a basement membrane marker protein may be constructed by adding ordinary technical considerations to those skilled in the art to the usual conditions and operation methods in each method.
- a measurement system for a basement membrane marker protein may be constructed by adding ordinary technical considerations to those skilled in the art to the usual conditions and operation methods in each method.
- Hiroshi Irie “Radioimmunoassay” Kelsha, published in 1974
- Hiroshi Irie “Continue Radioimmunoassay” published in Kodansha, 1974
- Enzyme Immunoassay edited by Eiji Ishikawa et al. 53)
- an angiogenic cell layer may be directly laminated, or an angiogenic cell layer may be laminated via another layer.
- the retinal pigment epithelial cell layer and the angiogenic cell layer are preferably laminated directly.
- the present invention also relates to a cell sheet comprising a retinal pigment epithelial cell layer and an angiogenic cell layer obtained by the production method of the present invention.
- the cell sheet of the present invention preferably includes a cell layer formed by retinal pigment epithelial cells obtained by inducing differentiation of stem cells or progenitor cells in vitro and an angiogenic cell layer.
- the cell sheet of the present invention further includes a basement membrane secreted from the retinal pigment epithelial cell layer.
- the cell sheet of the present invention is suitable as a transplant material for retinal treatment for patients with eye diseases.
- eye diseases include age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy, retinal detachment, central retinal artery occlusion, central retinal vein occlusion, choroidal atrophy, retinal pigment epithelial detachment, uveitis (Behcet's disease) , Harada disease, etc.) and retina choroidal degenerative diseases such as advanced myopia (pathological myopia).
- the cell sheet of the present invention is accompanied by an angiogenic cell layer, the choroid can also be transplanted at a high engraftment rate against a disease in which the choroid is simultaneously damaged.
- the cell sheet obtained by the production method of the present invention is an ocular disease associated with retina choroidal atrophy, in which the therapeutic effect is difficult to be manifested in transplantation of retinal pigment epithelial cells alone among the above-mentioned reticulochoroidal degenerative diseases.
- the cell sheet of the present invention since the cell sheet of the present invention has a basement membrane composed of the same components as the living body, it can also be used for various screening applications such as drug efficacy screening and toxicity evaluation for the eye diseases.
- the drug efficacy screening for the eye disease for example, according to the method described in JP-T-2007-500509, the cell sheet of the present invention can be applied to screening for a substance having a drug efficacy for the eye disease.
- the cell sheet of the present invention is subjected to stress conditions (for example, light (for example, white light, blue light; Can cause death of retinal cells, especially photoreceptor cells and can be a macular degeneration-inducing factor), A2E [retinoid N-retinylidene-N-retinyl-ethanolamine] (accumulation of A2E is neurodegeneration of age-related retinal cells) , Especially thought to contribute to the development of macular degeneration), tobacco smoke aggregates (smoking is considered a risk factor for macular degeneration), external pressure (eg, hydrostatic pressure; increased intraocular pressure is associated with glaucoma The number of photoreceptors expressing rhodopsin and immunostaining using an anti-caspase 3 antibody can be evaluated.
- stress conditions for example, light (for example, white light, blue light; Can cause death of retinal cells, especially photoreceptor cells and can be a macular degeneration-inducing factor), A2E [retinoid N-
- the cell sheet of the present invention can be applied to screening for toxic substances according to, for example, the method described in JP-T-2007-517210. Specifically, in the presence or absence of a toxic candidate substance, the cell sheet of the present invention is cultured using the integrin marker peptide described in JP-T-2007-517210, excited with a 488 nm wavelength laser, and at 520 nm. It can be evaluated by detecting fluorescence. Furthermore, the cell sheet of the present invention provides retinal pigment epithelial cells in vivo such as functions relating to maintenance of photoreceptor cells such as phagocytic ability and neuroprotective action of photoreceptor outer segments, retinal blood vessel barrier function by pump action, and tight junction. It can also be used as an in-vitro model for evaluating various functions included in.
- the cell sheet for transplantation of the present invention has the above-mentioned diseases in humans and mammals other than humans (eg, monkeys, mice, rats, dogs, cows, horses, pigs, sheep, goats, cats, rabbits, hamsters, guinea pigs, etc.). Can be used to treat.
- mammals other than humans eg, monkeys, mice, rats, dogs, cows, horses, pigs, sheep, goats, cats, rabbits, hamsters, guinea pigs, etc.
- the range of applicable disease sites of the cell sheet for transplantation of the present invention is appropriately selected depending on the target disease, the animal species to be administered, age, sex, weight, symptoms and the like.
- the cell sheet for transplantation of the present invention may be transplanted at once or divided into several times.
- the number of times of transplantation is determined according to the medical staff and guidelines according to the disease. For example, when the disease is age-related macular degenerative disease, the cell sheet for transplantation according to the present invention is selected according to its severity. You may transplant more than once. In the case of performing transplantation multiple times, the interval is not particularly limited, but a period of several days to several weeks may be set.
- the cell sheet for transplantation of the present invention is transplanted according to an appropriate transplantation method in accordance with medical staff and guidelines.
- the retinal pigment epithelial cell sheet of the present invention is transplanted under the retina, it can be carried out not only by a transplantation method in which it is placed in a water stream from an injection needle inserted into the transplantation site under the eyeball retina, but also by a dedicated transport treatment instrument.
- Production Example 1 Preparation of Retinal Pigment Epithelial Cells
- a retinal pigment epithelial cell used in Production Example 2 below, a mature retinal pigment epithelial cell (253G1, 253G1, differentiation-induced from human iPS cells according to the method described in Neuroscience Letters 458 (2009) 126-131) K11PD2, 59M8, 59SV2, 59SV3, 59SV9, 46a, K21EV15, 101EV3, K11EV9, 454E2), and retinal pigment epithelial cells (hES, CMK6) induced to differentiate from ES cells were used.
- hES retinal pigment epithelial cells
- 253G1 is a retinal pigment epithelial cell induced to differentiate from a human iPS cell (253G1) derived from a healthy person described in Nature Biotechnology 26, 101-106, 2008.
- 59SV2, 59SV3, and 59SV9 are retinal pigment epithelial cells derived from human iPS cells derived from the same retinitis pigmentosa patient. Jpn. Acad. , Ser.
- cells established by introducing Oct3 / 4, Sox2, Klf4, and c-Myc into human skin-derived fibroblasts using Sendai virus. is there.
- K21EV15, 101EV3, K11EV9, 454E2 are retinal pigment epithelial cells derived from different human retinitis pigmentosa and induced to differentiate from human iPS cells.
- the iPS cells are obtained from Nat Methods. 2011 May; 8 (5):
- human Oct3 / 4, Sox2, Klf4, L-Myc, and LIN28 are introduced into human skin-derived fibroblasts using an episomal vector. It is a cell established by the method.
- ⁇ Monkey iPS-derived retinal pigment epithelial cells> 46a is described in Jpn. J. et al. Transplant.
- hES is a retinal pigment epithelial cell derived from human ES cell line khES-1.
- CMK6 is a retinal pigment epithelial cell induced to differentiate from monkey ES cells according to the method described in Neuroscience Letters 458 (2009) 126-131.
- Production Example 2 Method for producing retinal pigment epithelial cell sheet ⁇ Preparation of collagen gel mixed solution> The following A liquid, B liquid, and C liquid were prepared.
- Solution A Pig tendon-derived acid-soluble Type-I collagen Cellmatrix IA (Nitta gelatin) 3.0 mg / ml
- Solution B 3 g of concentrated culture solution DMEM / F12 (Invitrogen, 12500-062) having a 5-fold concentration was dissolved in MilliQ water, and 50 ml of total volume was filtered.
- Solution C 5 ml of reconstitution buffer 1N NaOH (50 mM), NaHCO 3 3 (260 mM) 2.2 g and HEPES (200 mM) 4.77 g are dissolved in MilliQ water, and 100 volume of total volume is filtered. Mixing without cooling B liquid (7 vol) to B liquid (7 vol) (Light yellow). Next, C liquid (1 volume) was added and mixed (light pink) to obtain a 0.21% collagen gel mixed solution.
- F10-10% FBS F-10 (Sigma, N6908) 445 ml, FBS 50 ml, Penicillin-Streptomycin (Invitrogen, 15140-122) 5 ml
- F10-10% FBS F-10 (Sigma, N6908) 445 ml, FBS 50 ml, Penicillin-Streptomycin (Invitrogen, 15140-122) 5 ml
- F10-10% FBS F-10 (Sigma, N6908) 445 ml, FBS 50 ml, Penicillin-Streptomycin (Invitrogen, 15140-122) 5 ml
- the cells were cultured with F10-10% FBS until the retinal pigment epithelial cells became confluent. After confluence, the medium was 350 ml of SFRM-B27 (DMEM (Sigma, D6046), 150 ml of F12 HAM (Sigma, N6658), B27 (Invitrogen, 17504).
- collagenase L (collagenase L: Nitta gelatin, PBS (+): Sigma, 2600 U / ml) was added under the insert, incubated at 37 ° C. for 60 minutes, and washed 3 times with PBS (+).
- SFRM-B27 was added dropwise so that the retinal pigment epithelial cell sheet did not dry, and it was excised to a desired size with PALM MicroBeam (ZEISS).
- ZEISS PALM MicroBeam
- Example 1 Production of laminated cell sheet of vascular endothelial progenitor cell layer and retinal pigment epithelial cell layer ⁇ Preparation of vascular endothelial progenitor cells> Using endothelial cell culture kit-2 (EGM-2 medium (containing 2% FBS); manufactured by Takara Bio Inc., B3162), human vascular endothelial progenitor cells (ECFCs; manufactured by Takara Bio Inc., PT 056) were added at 1.3 ⁇ 10 4. as the cells / cm 2, the temperature-responsive culture dish (3.5 cm dish; Cellseed Co., CS3007) were seeded into.
- EMM-2 medium containing 2% FBS
- ECFCs human vascular endothelial progenitor cells
- the cells were washed once with EGM-2 medium, and the obtained cell sheet was transferred to a culture dish for adherent cells (Lumox dish 35; manufactured by Greiner, 077331; bottom surface can be cut off with a scalpel).
- a laser microdissection (PALM MicroBeam; manufactured by ZEISS)
- the cell sheet was excised to a desired size to obtain a cell sheet in which human vascular endothelial progenitor cells and human retinal pigment epithelial cells were laminated.
- Example 2 Cell Sheet Transplantation
- the laminated cell sheet obtained in Example 1 was transplanted subcutaneously into the latissimus dorsi of NOD / SCID mice, and a tissue section was prepared one week later.
- anti-CD31 antibody endothelial cells
- anti-HLA-1 antibody transplanted human cells
- DAPI engraftment of the transplanted cell sheet and formation of vasculature derived from the transplanted cells were observed.
- FIG. 1 arrow “capillary (donor)”. From this result, it was confirmed that vascular endothelial progenitor cells were able to mature into endothelial cells and form blood vessels after transplantation.
- Example 3 Cell Sheet Transplantation
- the laminated cell sheet obtained in Example 1 is transplanted under the retina of a rabbit partially deficient in retinal pigment epithelial cells and choroid, and a tissue section is prepared one week later.
- the engraftment of the transplanted cell sheet and the angiogenesis derived from the transplanted cells can be confirmed by immunohistochemistry using anti-CD31 antibody (endothelial cells), anti-HLA-1 antibody (transplanted human cells), and DAPI.
- Comparative Example 1 The human retinal pigment epithelial cell sheet (without human vascular endothelial progenitor cells) obtained in Production Example 2 was transplanted under the retina of a rabbit partially deficient in retinal pigment epithelial cells and choroid, and a tissue section was obtained one week later. create.
- anti-CD31 antibody endothelial cells
- anti-HLA-1 antibody transplanted human cells
- DAPI DAPI
- F10-1 The retinal pigment epithelial cell sheet prepared in Production Example 2 was placed in the insert of a 12 mm transwell insert (0.4 ⁇ m Pore Polyester membrane; Corning, 3460), and F10-10% FBS was placed in the insert and The cells were cultured for one day with 500 ⁇ l and 1500 ⁇ l added to the insert, respectively, and the culture supernatant was collected. The result of using this culture supernatant as an angiogenic medium is shown as “F10-1” in FIG.
- F10-2 The retinal pigment epithelial cell sheet prepared in Production Example 2 was placed in the insert of a 12 mm transwell insert (0.4 ⁇ m Pore Polyester membrane; Corning, 3460), and F10-10% FBS was placed in the insert and The cells were cultured for 2 days with 500 ⁇ l and 1500 ⁇ l added to the outside of the insert, and the culture supernatant was collected. The result of using this culture supernatant as an angiogenic medium is shown as “F10-2” in FIG.
- Angiogenesis Human vascular endothelial progenitor cells (ECFCs; manufactured by Takara Bio Inc., PT056) were seeded on each culture dish using the above four types of culture media so as to be 1.3 ⁇ 10 4 cells / cm 2 .
- the temperature was kept at 37 ° C. and 5% CO 2 , and the number of angiogenesis was counted under a microscope after 4 hours. The results of repeating the experiment three times are shown in FIG. 2A for each medium using the obtained number of angiogenesis ( * P ⁇ 0.001; ANOVA, Scheffe test).
- Angiogenesis was confirmed morphologically by optical and fluorescent micrographs, respectively.
- the concentration of VEGF in the four types of medium used was measured.
- EM was 1.44 ng / ml
- F10 was 0 ng / ml
- F10-1 was 2.64 ng / ml
- F10-2 was 2.80 ng / ml.
- F10 without VEGF had a significantly lower number of vessels. Since the number of angiogenesis was large in media other than F10, it was confirmed that VEGF promotes angiogenesis of vascular endothelial progenitor cells.
- angiogenesis was promoted by the culture supernatant of retinal pigment epithelial cells, so that angiogenesis treatment was performed in the state of a cell sheet in which a vascular endothelial precursor cell layer and a retinal pigment epithelial cell layer were laminated. It was confirmed that it was possible.
- Reference Example 2 Use of Matrigel Human vascular endothelial progenitor cells were cultured using four types of medium in the same manner as in Reference Example 1 except that a Matrigel-coated culture dish was used, and the number of angiogenesis was counted. The result of repeating the experiment three times is shown in FIG. 2B for each medium using the obtained number of angiogenesis ( * P ⁇ 0.01 ** P ⁇ 0.05; ANOVA, Scheffe test). ). Angiogenesis was confirmed morphologically by optical and fluorescent micrographs, respectively. Compared to Reference Example 1, when Matrigel was used, the number of angiogenesis was significantly improved in all media. In particular, F10 not containing VEGF had a remarkably low number of vascular formations (Reference Example 1). However, when Matrigel was used, promotion of vascularization was observed. From these results, it was confirmed that angiogenesis could be promoted using Matrigel regardless of the presence of VEGF.
- Reference conditions for production conditions of retinal pigment epithelial cell sheet Method for producing retinal pigment epithelial cell sheet (type of collagen) In the step of preparing a cell sheet using 253G1 (iPS-retinal pigment epithelial cells) of Production Example 2, 3 mg / ml of porcine tendon-derived acid-soluble Type-I collagen Cellmatrix IA (Nitta gelatin) was 0.21.
- A Pig skin-derived Type-I collagen TE (special order product: mainly containing type I collagen and some type III collagen) (Nitta gelatin) 5 mg / ml 0.35% collagen mixed solution / well
- B Type 10-I collagen T-1002 derived from porcine tendon (special order product: type I collagen) (Nitta gelatin), 0.35% collagen mixed solution / Well
- C FITC-labeled collagen I (Chondrex) 1 mg / ml in 0.07% collagen mixed solution / Well
- D FITC-labeled collagen I (custom) (Chondrex) 3 mg / ml 0.21% collagen mixed solution / well
- E Atelocollagen (Koken) 3 mg / ml 0.21% collagen mixed solution / Well
- F A cell sheet was prepared in the same manner as in Production Example 2 except that it was used as a permeable collagen membrane for cell culture (Koken), and the retinal pigment epithelial cell sheet
- Reference Example 4 Method for producing retinal pigment epithelial cell sheet (collagen content)
- the amount of collagen gel mixed solution used was changed to 100 ⁇ l or 300 ⁇ l instead of 200 ⁇ l, and Production Example 2
- a retinal pigment epithelial cell sheet was recovered by preparing and cutting out a cell sheet by the same method.
- the amount of collagen gel mixed solution used is 100 ⁇ l
- the amount of collagen gel mixed solution is small, so a collagen gel layer with a thin central part is formed due to the influence of surface tension, and when the culture proceeds,
- the seeded retinal pigment epithelial cells are likely to be in direct contact with the membrane at the bottom, and the retinal pigment epithelial cell sheet may be torn during sheet cutting.
- the amount of the collagen gel mixed solution used is 300 ⁇ l, the amount of the collagen gel mixed solution is large, so that a thick collagen gel layer is formed, and the amount of medium that can be relatively retained in the insert is reduced and maintained.
- the culture is difficult to perform, and the collagenase treatment takes time, so that damage to the cell sheet may increase.
- Reference Example 5 Method for producing retinal pigment epithelial cell sheet (amount of collagenase and treatment time) In the step of preparing a cell sheet using 253G1 (iPS-retinal pigment epithelial cells) of Production Example 2, 30 ⁇ l of 1% collagenase L (Nitta gelatin) or type I collagenase (Roche) was used to form a retinal pigment epithelial cell sheet.
- the cells were prepared in the same manner as in Production Example 2 except that 10 ⁇ l was 10 min, 10 ⁇ l was 20 min, 10 ⁇ l was 30 min, 10 ⁇ l was 60 min, 20 ⁇ l was 20 min, 20 ⁇ l was 20 min, 20 ⁇ l was 60 min, and 30 ⁇ l was 50 min instead of the contact condition for 30 min.
- Retinal pigment epithelial cell sheets were collected by creating and cutting out sheets. As a result, when collagenase treatment was performed at 10 ⁇ l for 60 min or 20 ⁇ l for 60 min, collagen degradation as high as 30 min at 30 ⁇ l was observed.
- Reference Example 6 Method for producing retinal pigment epithelial cell sheet (number of seeded cells)
- the number of cells seeded in the insert was changed to 5 ⁇ 10 5 cells / 500 ⁇ l, and (A) 5 ⁇ 10 4 / 500 ⁇ l, (B) 1 ⁇ 10 5 / 500 ⁇ l, the (C) 1 ⁇ 10 6 / than 500 [mu] l and the point creates a cell sheet in the same manner as in example 1, retinal pigment epithelial cell sheet by cutting It was collected.
- (A) and (B) have a long time until cells become confluent because the number of cells is small, and (C) has a long time until cells become confluent with slow growth. Tended to be.
- the retinal pigment epithelial cell sheet had a monolayer epithelial morphology from the state of nuclear staining using 4 ′, 6-diamidino-2-phenylindole (DAPI; 1 ⁇ g / ml) manufactured by Molecular Probes. .
- DAPI 6-diamidino-2-phenylindole
- retinal pigment epithelial cell sheets were prepared for cell sheets prepared from 253G1 (iPS-retinal pigment epithelial cells) and 454E2 (iPS-retinal pigment epithelial cells).
- the Apical side and Basal side culture solutions in the transwell were collected, and Arvydas M, IOVS. 2006; 47: 3612-3624
- the amounts of VEGF and PEDF produced were detected by ELISA.
- Arvydas M IOVS.
- VEGF is mainly secreted on the Basal side and PEDF is mainly secreted on the Apical side, similar to the retinal pigment epithelium derived from human fetus reported in 2006; 47: 3612-3624 (FIG. 4). ). It was shown that the retinal pigment epithelial cell sheet prepared from 253G1 and 454E2 in Production Example 2 has the same cytokine secretion ability as in vivo and is excellent in functionality.
- Transepithelial electrical resistance of retinal pigment epithelial cell sheet There is a strong correlation between the barrier function of the cell layer and electrical resistance, so-called transepithelial / endothelial electrical resistance (TER).
- TER transepithelial / endothelial electrical resistance
- the cross-section of the fundus was imaged like a tissue section using an optical coherence tomography, and the state of the retina was confirmed. There was no leakage of fluorescence due to the fluorescence fundiography, and the graft was engrafted. There were no obstacles such as thinning of the retina.
- the monkey retinal pigment epithelial cell sheet prepared from monkey iPS cell-derived retinal pigment epithelial cell 46a in Production Example 2 was obtained from Invest Ophthalmol Vis Sci. 1995 Feb; 36 (2): 381-90. Were transplanted under the retina of one autograft eye and three autograft eyes. Until one year after transplantation, the cross-section of the fundus was imaged like a tissue slice using a fundus photograph and an optical coherence tomography (OCT) optical coherence tomography, and the state of the retina was followed up.
- OCT optical coherence tomography
- Obvious rejection was observed, such as fibrotic changes around one side, leakage of fluorescence by fluorescence fundiography, and high intensity lesions under the retina in OCT.
- autologous transplantation did not show such obvious rejection, there was no leakage of fluorescence by fluorescence fundiography, the graft was engrafted, and there was no obstacle such as thinning of the sensory retina .
- the present invention it is possible to easily and stably prepare a laminated sheet of retinal pigment epithelial cells having a blood vessel constituent cell layer that can compensate for deficient choroidal blood vessels in a living body and supply oxygen and nutrients to the retina after transplantation.
- the cell sheet of the present invention is excellent in engraftment rate and functionality, it has a sufficient therapeutic effect only by retinal pigment epithelial cell transplantation, such as retina choroidal degenerative disease, particularly intense myopia and severe uveitis accompanied by retina choroidal atrophy. Since it is possible to treat severe retina-choroidal degenerative diseases that are difficult to obtain, it is extremely useful.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Vascular Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
[1]網膜色素上皮細胞層と血管形成細胞層とを積層する工程を含む、網膜色素上皮細胞層及び血管形成細胞層を含む細胞シートの製造方法。
[2]血管形成細胞層が網膜色素上皮細胞層の基底面と接触するように、網膜色素上皮細胞層と血管形成細胞層とを積層する、[1]記載の製造方法。
[3]血管形成細胞層が、血管芽細胞、血管内皮前駆細胞、及び血管内皮細胞からなる群から選択される少なくとも一つの細胞で構成されている、[1]又は[2]記載の製造方法。
[4]血管形成細胞層が、細胞シートの移植対象となる患者由来組織若しくは細胞、又は患者とHLA型が適合するドナー由来細胞で構成されている、[1]又は[2]記載の製造方法。
[5]網膜色素上皮細胞層が、以下の工程を含む方法で製造される細胞シートである、[1]~[4]のいずれかに記載の製造方法:
(1)コラーゲンゲル上に網膜色素上皮細胞を播種、培養し、網膜色素上皮細胞で構成された細胞シートを形成させる工程、
(2)コラーゲンゲルをコラゲナーゼで分解し、網膜色素上皮細胞で構成された細胞シートを剥離する工程。
[6]網膜色素上皮細胞が、ES細胞、iPS細胞又は前駆細胞を分化誘導して得られた細胞である[1]~[5]のいずれかに記載の製造方法。
[7][1]~[6]のいずれかに記載の方法で製造された細胞シート。
[8]生体外で幹細胞又は前駆細胞を分化誘導して得られた網膜色素上皮細胞で形成された細胞層、当該細胞から分泌された基底膜、及び血管形成細胞層を含む移植用細胞シート。
本発明は、網膜色素上皮細胞層と血管形成細胞層とを積層する工程を含む、網膜色素上皮細胞層及び血管形成細胞層を含む細胞シートの製造方法(本発明の製造方法)を提供する。
本発明における血管形成細胞層は、血管形成能を有する細胞(血管形成細胞)で構成されている。本発明の製造方法により得られる細胞シートを網膜変性症患者の脈絡膜欠損部位へ移植すると、移植部位において当該細胞シートに含まれる血管形成細胞が血管(好ましくは、脈絡膜血管)を再構成することにより網膜色素上皮細胞への酸素や栄養分の供給等を担う。そのため、本発明の製造方法により得られる細胞シートは、特に脈絡膜欠損を伴う網膜変性疾患の患者の脈絡膜欠損部位に移植することにより優れた治療効果を発揮することができる。
本発明において用いられる網膜色素上皮細胞は、眼球から直接採取した初代細胞でもよく、あるいは、それらを何代か継代させたものでもよい。初代網膜色素上皮細胞は公知の方法で単離することができ、例えば、眼球由来の網膜色素上皮細胞は死体眼球摘出後、速やかに赤道部で眼球を分割し、硝子体と網膜を除去した後、必要に応じてコラゲナーゼやヒアルロニダーゼ等で処理し、セルスクレーパーによる擦過またはトリプシンやEDTA溶液にて細胞をブルッフ膜より遊離させて回収した後、培養液の中で静置することにより培養皿への接着、増殖を誘導することにより必要量の細胞を増殖させ、トリプシン処理などで適宜継代し十分な細胞数を確保することができる。
(1)コラーゲンゲル上に網膜色素上皮細胞を播種、培養し、網膜色素上皮細胞で構成された細胞シートを形成させる工程;及び
(2)コラーゲンゲルをコラゲナーゼで分解し、網膜色素上皮細胞で構成された細胞シートを剥離する工程。
コラーゲン法で得られる網膜色素上皮細胞から構成される細胞シートは、網膜色素上皮細胞特有のサイトカインが生体内と同様の極性をもって分泌しており、また細胞間の密着結合の指標となる経上皮電気抵抗(TER)が生体内と同様に上昇していたことから生体内と同様の細胞層のバリア機能を有している。コラーゲン法によれば、このように、生体内と同様の機能を有する網膜色素上皮細胞から構成される細胞シートを得ることができる。
一般に、網膜色素上皮細胞は、培養皿の上で培養した場合、基底膜成分を産生するものの、培養皿から剥離して使用可能な状態の網膜色素上皮細胞シートとして剥離することが極めて困難であるが(Invest.Ophthalmol.Vis.Sci.,36(2),1995,381-390)、コラーゲン法によれば、人工膜を利用することなく、網膜色素上皮細胞から産生された基底膜を伴う網膜色素上皮細胞をシートとして回収することが可能である。また、網膜色素上皮細胞は単層構造であるため、それ単独で扱おうとするとシート構造が崩壊し、細胞単位にばらばらになってしまいシートとして移植することが極めて困難であった。一方、コラーゲン法により得られる網膜色素上皮細胞から構成される細胞シートは、基底膜を伴い十分な剛性を有するため、シートの回収時にしわになりにくく、取扱いが極めて容易となる。そのため、血管形成細胞層との積層操作を円滑に行うことができる。また、細胞移植デバイスへの搭載や移植操作を円滑に行うことができるため、細胞移植を最小限の侵襲で実施でき、効果、予後、ともに向上することが期待される。また、コラーゲン法により得られる網膜色素上皮細胞から構成される細胞シートが基底膜を伴うことは、基底膜も同時に障害を受けている疾患に対する移植用途として極めて有利である。例えば、加齢黄斑変性は、ブルッフ膜も障害を受けている場合があるが、コラーゲン法により得られる網膜色素上皮細胞シートを、上記本発明の製造方法における網膜色素上皮細胞層として用いることにより、当該方法により製造される細胞シートが有する基底膜がその障害部分を補うことにより、細胞シートの生着率を向上させることができ、これによる治療効果も期待できる。このため、本発明の製造方法において、コラーゲン法により得られる網膜色素上皮細胞シートを網膜色素上皮細胞層として用いると、製造される細胞シートは、基底膜の障害を伴う疾患を対象とする移植用シートとして好適であり、特に加齢黄斑変性を対象とする移植用シートとして好適に利用できる。
(3)剥離された細胞シートのコラーゲンゲルとの接触面に基底膜の有無を確認する工程
尚、各マーカータンパク質に対する抗体は、該マーカータンパク質または該タンパク質、あるいはその部分ペプチドを感作抗原として、通常使用されるポリクローナル抗体またはモノクローナル抗体作製技術に従って取得することができる。
下記製造例2に用いる網膜色素上皮細胞として、Neuroscience Letters 458(2009)126-131に記載の方法に準じて、ヒトiPS細胞から分化誘導した成熟網膜色素上皮細胞(253G1、K11PD2、59M8、59SV2、59SV3、59SV9、46a、K21EV15、101EV3、K11EV9、454E2)、及びES細胞から分化誘導した網膜色素上皮細胞(hES,CMK6)を用いた。
<ヒトiPS由来網膜色素上皮細胞>
253G1は、Nature Biotechnology 26,101-106,2008に記載された健常者に由来するヒトiPS細胞(253G1)から分化誘導した網膜色素上皮細胞である。
59SV2、59SV3、59SV9は、同一の網膜色素変性症患者に由来するヒトiPS細胞から分化誘導した網膜色素上皮細胞であり、同iPS細胞は、Proc.Jpn.Acad.,Ser.B 85(2009)348-362に記載の方法に準じて、センダイウィルスを用いて、ヒト皮膚由来線維芽細胞にOct3/4、Sox2、Klf4、c-Mycを導入する方法で樹立された細胞である。
K21EV15、101EV3、K11EV9、454E2は互いに異なる網膜色素変性症患者に由来する、ヒトiPS細胞から分化誘導した網膜色素上皮細胞であり、同iPS細胞は、Nat Methods.2011 May;8(5):409-12に記載の方法に準じて、エピソーマルベクターを用いて、ヒト皮膚由来線維芽細胞にヒトOct3/4、Sox2、Klf4、L-Myc、LIN28を導入する方法で樹立された細胞である。
<サルiPS由来網膜色素上皮細胞>
46aは、Jpn.J.Transplant.44(2009)231-235に記載の方法に従ってサル(cynomolgus monkey)iPS細胞から分化誘導した網膜色素上皮細胞である。
<ES由来網膜色素上皮細胞>
hESは、ヒトES細胞株khES-1から分化誘導した網膜色素上皮細胞である。CMK6は、Neuroscience Letters 458(2009)126-131に記載の方法に準じて、サルES細胞から分化誘導した網膜色素上皮細胞である。
<コラーゲンゲル混合溶液の調製>
以下のA液、B液及びC液を調製した。
A液:ブタ腱由来酸可溶性
Type-IコラーゲンCellmatrix I-A(新田ゼラチン)3.0mg/ml
B液:5倍濃度の濃縮培養液
DMEM/F12(Invitrogen、12500-062)3gをMilliQ水に溶解させ、total volume 50mlをフィルター処理
C液:再構成用緩衝液
1N NaOH (50mM)5ml、NaHCO3(260mM)2.2g、HEPES(200mM)4.77gをMilliQ水に溶解させ、total volume 100mlをフィルター処理
冷却しながらA液(7容量)にB液(2容量)を泡立てないように混合(薄黄色)した。次に、C液(1容量)を加え混合(薄ピンク色)し、0.21%コラーゲンゲル混合溶液とした。
<網膜色素上皮細胞シートの作成>
12mmトランスウェルインサート(0.4μm Pore Polyester メンブレン;Corning、3460)のインサート内に0.21%コラーゲンゲル混合溶液を200μl加え、37℃で30minインキュベートした。次に、F10-10%FBS(F-10(Sigma、N6908)445ml,FBS 50ml,Penicilin-Streptomycin(Invitrogen、15140-122)5ml)をインサート外に1500μl、インサート内に500μl加え、37℃で24hrインキュベートした。その後、インサート内およびインサート外をF10-10%FBSで1回洗浄し、インサート内に製造例1で得た網膜色素上皮細胞を5×105個(F10-10%FBS,500μl)となるように播種し、インサート外にF10-10%FBSを1500μl加えた。網膜色素上皮細胞がコンフルエントになるまでF10-10%FBSで培養し、コンフルエント後、培地をSFRM-B27(DMEM(Sigma、D6046)350ml,F12 HAM(Sigma、N6658)150ml,B27(Invitrogen、17504-044)10ml,200mM L-Glutamine(Sigma、G7513)5ml,Penicilin-Streptomycin(Invitrogen、15140-122)5ml,bFGF(wako、060-04543)10ng/ml)に交換し(インサート外1500μl、インサート内500μl、培地交換は3回/week)網膜色素上皮細胞の色や形が適当になるまで培養した。
<切り出し>
培養開始から6週間経過後、インサートのメンブレンを切除した。コラゲナーゼ L(コラゲナーゼ L:新田ゼラチン,PBS(+):Sigma,2600U/ml)100μlをインサート下に加え、37℃で60分インキュベートしPBS(+)で3回洗浄した。網膜色素上皮細胞シートが乾かないようにSFRM-B27を滴下し、PALM MicroBeam(ZEISS)にて好みの大きさに切除した。
<特性>
組織切片に対する免疫組織化学により、作成した細胞シートは、タイトジャンクション(ZO-1陽性)が形成された網膜色素上皮細胞シートが、基底膜(ラミニン、IV型コラーゲン陽性)に裏打ちされた構造を有し、シート形成に用いた1型コラーゲンの残存がないこと(Collagen type1陰性)が確認された。
<血管内皮前駆細胞の調製>
内皮細胞培養キット-2(EGM-2培地(2% FBS含有);タカラバイオ社製、B3162)を用い、ヒト血管内皮前駆細胞(ECFCs;タカラバイオ社製、PT056)を1.3×104cells/cm2となるように、温度応答性培養皿(3.5cm dish;セルシード社製、CS3007)へ播種した。
<血管内皮前駆細胞の網膜色素上皮細胞シートへの重層>
15hr経過後、温度応答性培養皿に、製造例1で得たヒトiPS細胞由来網膜色素上皮細胞シートを入れて血管内皮前駆細胞へ重ねて置き、培地を静かに吸引して、細胞シートが温度応答性培養皿の中央部分にくるように配置した。その後、乾燥防止のために20℃のEGM-2培地を100μl添加して、30分間静置することにより、培養皿表面の温度応答性ポリマーを親水性に転換させ、細胞シートを剥離した。
EGM-2培地で1回洗浄し、得られた細胞シートを、付着細胞用培養皿(Lumox dish 35;グライナー社製、077331;底面をメスで切り取り可能)に移した。レーザマイクロダイセクション(PALM MicroBeam;ZEISS社製)を用いて細胞シートを好みの大きさに切除して、ヒト血管内皮前駆細胞とヒト網膜色素上皮細胞が積層された細胞シートを得た。
実施例1で得た積層細胞シートを、NOD/SCIDマウス広背筋の皮下に移植し、1週間後に組織切片を作成した。抗CD31抗体(内皮細胞)、抗HLA-1抗体(移植ヒト細胞)、DAPIを用いた免疫組織化学の結果、移植した細胞シートの生着と、移植細胞に由来する脈管構造の形成が認められた(図1中、矢印「capillary (donor)」)。この結果から、血管内皮前駆細胞が、移植後に内皮細胞へ成熟し、脈管を形成し得たことを確認した。
実施例1で得た積層細胞シートを、部分的に網膜色素上皮細胞と脈絡膜とを欠損させたウサギの網膜下に移植し、1週間後に組織切片を作成する。抗CD31抗体(内皮細胞)、抗HLA-1抗体(移植ヒト細胞)、DAPIを用いた免疫組織化学により、移植した細胞シートの生着と、移植細胞に由来する脈管形成を確認できる。
製造例2で得たヒト網膜色素上皮細胞シート(ヒト血管内皮前駆細胞なし)を、部分的に網膜色素上皮細胞と脈絡膜とを欠損させたウサギの網膜下に移植し、1週間後に組織切片を作成する。抗CD31抗体(内皮細胞)、抗HLA-1抗体(移植ヒト細胞)、DAPIを用いた免疫組織化学により、移植細胞はシート構造が破壊し、少数が分散した状態で検出され、実施例3と比較して、移植細胞の生着率が著しく低下する現象が認められる。
VEGFを含む培地で培養した血管内皮前駆細胞が脈管を形成することを次の方法で確認した。
(培地)
「EM」:EGM-2培地(2% FBS含有;タカラバイオ社製、B3162)
「F10」:F10-10%FBS(F-10(Sigma、N6908)445ml,FBS 50ml,Penicilin-Streptomycin(Invitrogen、15140-122)5ml)。この培地を脈管形成用培地として用いた結果を図2中「F10」と示す。
「F10-1」:製造例2で作成した網膜色素上皮細胞シートを、12mmトランスウェルインサート(0.4μm Pore Polyester メンブレン;Corning、3460)のインサート内に置き、F10-10%FBSをインサート内およびインサート外にそれぞれ500μl、1500μl加えた状態で一日培養し、培養上清を回収した。この培養上清を脈管形成用培地として用いた結果を図2中「F10-1」と示す。
「F10-2」:製造例2で作成した網膜色素上皮細胞シートを、12mmトランスウェルインサート(0.4μm Pore Polyester メンブレン;Corning、3460)のインサート内に置き、F10-10%FBSをインサート内およびインサート外にそれぞれ500μl、1500μl加えた状態で二日培養し、培養上清を回収した。この培養上清を脈管形成用培地として用いた結果を図2中「F10-2」と示す。
(脈管形成)
上記4種類の培地を用いて、それぞれ培養皿に、ヒト血管内皮前駆細胞(ECFCs;タカラバイオ社製、PT056)を1.3×104cells/cm2となるように播種した。37℃、5%CO2で保温し、4時間後に顕微鏡下で脈管形成数を数えた。3回実験を繰り返した結果を、図2(A)に、得られた脈管形成数を用いた培地ごとに示した(*P<0.001;ANOVA,Scheffe test)。それぞれ、光学顕微鏡写真及び蛍光顕微鏡写真により脈管形成を形態的に確認できた。
用いた4種類の培地中のVEGFの濃度を測定したところ、EMは 1.44ng/ml、F10は0ng/ml、F10-1は 2.64ng/ml、F10-2は2.80ng/mlであった。VEGFを含まないF10は脈管の形成数が著しく低かった。F10以外の培地では脈管形成数が多くみられたことから、VEGFにより血管内皮前駆細胞の脈管形成が促進させることが確認された。また、この結果より、網膜色素上皮細胞の培養上清により脈管形成を促進できたことから、血管内皮前駆細胞層と網膜色素上皮細胞層を積層した細胞シートの状態で脈管形成処理を施すことも可能であることが確認できた。
マトリゲルコートした培養皿を用いた点以外は参考例1と同様の方法で、4種類の培地を用いてヒト血管内皮前駆細胞を培養し、脈管形成数を数えた。3回実験を繰り返した結果を、図2(B)に、得られた脈管形成数を用いた培地ごとに示した(*P<0.01 **P<0.05;ANOVA,Scheffe test)。それぞれ、光学顕微鏡写真及び蛍光顕微鏡写真により脈管形成を形態的に確認できた。
参考例1と比較して、マトリゲルを用いた場合はすべての培地において脈管形成数が著しく向上した。特に、VEGFを含まないF10は脈管の形成数が著しく低かったが(参考例1)、マトリゲルを用いた場合は脈管形成の促進が認められた。これらの結果より、VEGFの存在に関わらず、マトリゲルを利用して脈管形成を促進しうることが確認できた。
参考例3.網膜色素上皮細胞シートの製造方法(コラーゲンの種類)
製造例2の253G1(iPS-網膜色素上皮細胞)を用いた細胞シートを作成する工程において、ブタ腱由来酸可溶性のType-IコラーゲンCellmatrix I-A(新田ゼラチン)3mg/mlを0.21%コラーゲン混合溶液/wellとして用いるのに代えて、(A)ブタ皮由来Type-IコラーゲンTE(特注品:主にI型コラーゲン、若干のIII型コラーゲンを含む)(新田ゼラチン)5mg/mlを0.35%コラーゲン混合溶液/well、(B)ブタ腱由来Type-IコラーゲンT-1002(特注品:I型コラーゲン)(新田ゼラチン)5.1mg/mlを0.35%コラーゲン混合溶液/well、(C)FITC標識コラーゲンI(Chondrex)1mg/mlを0.07%コラーゲン混合溶液/well、(D)FITC標識コラーゲンI(特注)(Chondrex)3mg/mlを0.21%コラーゲン混合溶液/well、(E)アテロコラーゲン(高研)3mg/mlを0.21%コラーゲン混合溶液/well、(F)細胞培養用透過性コラーゲン膜(高研)としてそれぞれ用いた点以外は製造例2と同様の方法で細胞シートを作成し、切り出すことにより網膜色素上皮細胞シートを回収した。
製造例2と前記の各コラーゲンを用いた場合の試験結果を4つの項目[1.ゲルの強度;2.細胞の接着;3.細胞の増殖;4.安全性]において比較・評価した。その結果、(A){1.劣る;2.同等;3.劣る;4.良}、(B){1.良(5.1mg/ml);2.同等;3.劣る;4.良}、(C){1.劣る(1mg/ml);2.劣る;3.不明 ;4.不明}、(D){1.同等(3mg/ml);2.同等;3.劣る;4.不明}、(E){1.同等(3mg/ml);2.劣る;3.不明;4.良}、(F){コラゲナーゼで溶解せず使用できなかった}であった。ゲルの強度に関して、網膜色素上皮細胞が増殖するためにはある程度の固さが求められる。このような観点からはコラーゲンの種類と濃度は、製造例2のブタ腱由来酸可溶性のType-IコラーゲンCellmatrix I-Aと(B)ブタ腱由来Type-IコラーゲンT-1002を上記の濃度で用いることが特に好適であった。基質がある程度固くない場合、網膜色素上皮が増殖しないため本発明の使用に耐えない。
製造例2の253G1(iPS-網膜色素上皮細胞)を用いた細胞シートを作成する工程において、コラーゲンゲル混合溶液の使用量を200μlに代えて、100μl、または300μlとした点以外は製造例2と同様の方法で細胞シートを作成し、切り出すことにより網膜色素上皮細胞シートを回収した。
製造例2と比較して、コラーゲンゲル混合溶液の使用量が100μlの場合はコラーゲンゲル混合溶液量が少ないため、表面張力の影響で中央部分が薄いコラーゲンゲル層が形成され、培養が進むと、播種した網膜色素上皮細胞が底部のメンブレンに直接接触しやすく、シートの切り出し作業時に網膜色素上皮細胞シートが破れる場合があった。コラーゲンゲル混合溶液の使用量が300μlの場合はコラーゲンゲル混合溶液量が多いため、厚みのあるコラーゲンゲルの層が形成され、相対的にインサート内に保持することができる培地の量が少なくなり維持培養が行いにくく、また、コラゲナーゼ処理に時間がかかるため細胞シートへのダメージが大きくなる恐れがある。
製造例2の253G1(iPS-網膜色素上皮細胞)を用いた細胞シートを作成する工程において、1%コラゲナーゼL(新田ゼラチン)又はI型コラゲナーゼ(ロシュ)を30μl用いて網膜色素上皮細胞シートに30min接触する条件に代えて、それぞれ10μlで10min、10μlで20min、10μlで30min、10μlで60min、20μlで20min、20μlで60min、30μlで50minとした点以外は製造例2と同様の方法で細胞シートを作成し、切り出すことにより網膜色素上皮細胞シートを回収した。
その結果、コラゲナーゼ処理を10μlで60min又は20μlで60min行った場合、30μlで30minと同程度のコラーゲンの分解が見られた。
製造例2の253G1(iPS-網膜色素上皮細胞)を用いた細胞シートを作成する工程において、インサート内に播種する細胞数を5×105個/500μlに代えて、(A)5×104/500μl、(B)1×105/500μl、(C)1×106/500μlとした点以外は実施例1と同様の方法で細胞シートを作成し、切り出すことにより網膜色素上皮細胞シートを回収した。
製造例2と比較して、(A)、(B)は細胞数が少ないため細胞がコンフルエントになるまでに時間が長く、(C)は増殖が遅くやはり細胞がコンフルエントになるまでの時間が長くなる傾向にあった。
製造例2において、253G1(iPS-網膜色素上皮細胞)から作成した細胞シートについて、cryo section(凍結切片)を作成し、免疫組織化学染色を行った。ZO-1の発現によりタイトジャンクションが形成されていること、ラミニン、IV型コラーゲンの発現により基底膜が構成されていることを確認した。各タンパク質の検出には、Zymed社製rabbit anti-ZO-1(1:100希釈)、Abcam社製rabbit laminin(1:200希釈)、Calbiochem社製mouse anti-human collagen type IV antibody(1:40)の各抗体を用いた。さらに、Molecular Probes社製4’,6-diamidino-2-phenylindole(DAPI;1μg/ml)を用いた核染色の状態から網膜色素上皮細胞シートは単層上皮形態をとっていることが確認された。
評価1.細胞シートの網膜色素上皮特異的遺伝子発現プロファイル
製造例2において、59SV3、59SV9(iPS-網膜色素上皮細胞)から細胞シートを作成する工程において、細胞がコンフルエントになってから培地をSFRM-B27へ交換した日を0日として、1週間、4週間、2カ月経過後のシートを構成する細胞について、RT-PCRによりBEST1、RPE65、MERTK、CRALBPの発現を確認したところ、ポジティブコントロール(ヒト網膜色素上皮細胞total RNA(ScienCell社製、Cat NO.6545))と同程度以上の発現が認められた。ここで、BEST1、RPE65、MERTKは網膜色素上皮細胞に特異的に発現する遺伝子である。また、CRALBPは網膜色素上皮細胞とミューラー細胞に発現する遺伝子である。
製造例2において、253G1(iPS-網膜色素上皮細胞)から作成した細胞シートについて、コラゲナーゼ処理前及び後に切り出した各シートについてcryo section(凍結切片)を作成し、免疫組織化学染色を行った。核をMolecular Probes社製4’,6-diamidino-2-phenylindole(DAPI;1μg/ml)で染色し、Collagen type1の染色にCalbiochem社製rabbit anti-human collagen type I antibody(1:40希釈)を用いたところ、コラゲナーゼ処理後のシートからはコラーゲンは検出されず、コラゲナーゼにより培養皿にコートしたコラーゲンが除去されていることを確認した。一方、コラゲナーゼ処理前に切り出したシートからはコラーゲンが検出された。
製造例2において、253G1(iPS-網膜色素上皮細胞)及び454E2(iPS-網膜色素上皮細胞)から作成した細胞シートについて、ぞれぞれ網膜色素上皮細胞シートを切り出す工程の前に、トランスウェル内のApical側及びBasal側の培養液を回収し、Arvydas M, IOVS.2006;47:3612-3624に記載の方法に準じて、ELISAでVEGF及びPEDFの産生量を検出した。その結果、Arvydas M, IOVS.2006;47:3612-3624で報告されているヒト胎児由来網膜色素上皮と同様、VEGFはBasal側に主に分泌され、PEDFはApical側に主に分泌されていることが確認された(図4)。製造例2において253G1及び454E2から作成した網膜色素上皮細胞シートは生体内と同様のサイトカイン分泌能を有し、機能性に優れていることが示された。
細胞層のバリア機能と電気抵抗、いわゆる経上皮/内皮電気抵抗(TER)には強い相関関係が見られる。製造例2において、454E2(iPS-網膜色素上皮細胞)から作成した細胞シートについて、網膜色素上皮細胞シートを切り出す工程の前に、MILLIPORE社記載の方法(Millicell ERS-2を使用)に準じて、インサートの内側と外側の培地中にプローブを入れ、TERを電気的に測定した。その結果、TERは640Ω・cm2であり、Nature Protocols vol4,No5 662-673 (2009)のFig10で報告されているヒト胎児由来網膜色素上皮と同様、高いTER値を示した。製造例2において作成した網膜色素上皮細胞シートは生体内の網膜色素上皮と同様の高いバリア機能を有していることが示された。
製造例2においてサルES細胞由来網膜色素上皮細胞、CMK6から作成したサル網膜色素上皮細胞シートを、Invest Ophthalmol Vis Sci.1995 Feb;36(2):381-90.に記載の方法に準じてサルの片眼に移植した。移植前に、移植予定の眼の網膜に障害を与える目的で網膜光凝固術を施し、網膜光凝固班を形成させたサルの片眼移植後28日目に、眼底写真、及びOCT(Optical coherence tomograph)光干渉断層計を用いて眼底の断面を組織切片のように画像化し、網膜の状態を確認したところ、蛍光眼底造影検査による蛍光の漏出はなく、移植片は生着しており、感覚網膜の菲薄化などの障害は起きていなかった。
製造例2においてサルiPS細胞由来網膜色素上皮細胞、46aから作成したサル網膜色素上皮細胞シートを、Invest Ophthalmol Vis Sci. 1995 Feb;36(2):381-90.に記載の方法に準じて自家移植1眼、他家移植3眼の網膜下に移植した。移植後1年後まで、眼底写真、及びOCT(Optical coherence tomograph)光干渉断層計を用いて眼底の断面を組織切片のように画像化し、網膜の状態を経過観察したところ、他家移植は移植片周囲の線維性変化や蛍光眼底造影検査による蛍光の漏出、OCTでは網膜下の高輝度病変といった明らかな拒絶反応がみられた。一方、自家移植ではこの様な明らかな拒絶反応は認められず、蛍光眼底造影検査による蛍光の漏出はなく、移植片は生着しており、感覚網膜の菲薄化などの障害は起きていなかった。
Claims (8)
- 網膜色素上皮細胞層と血管形成細胞層とを積層する工程を含む、網膜色素上皮細胞層及び血管形成細胞層を含む細胞シートの製造方法。
- 血管形成細胞層が網膜色素上皮細胞層の基底面と接触するように、網膜色素上皮細胞層と血管形成細胞層とを積層する、請求項1記載の製造方法。
- 血管形成細胞層が、血管芽細胞、血管内皮前駆細胞、及び血管内皮細胞からなる群から選択される少なくとも一つの細胞で構成されている、請求項1又は2記載の製造方法。
- 血管形成細胞層が、細胞シートの移植対象となる患者由来組織若しくは細胞、又は患者とHLA型が適合するドナー由来細胞で構成されている、請求項1又は2記載の製造方法。
- 網膜色素上皮細胞層が、以下の工程を含む方法で製造される細胞シートである、請求項1~4のいずれか1項に記載の製造方法:
(1)コラーゲンゲル上に網膜色素上皮細胞を播種、培養し、網膜色素上皮細胞で構成された細胞シートを形成させる工程、
(2)コラーゲンゲルをコラゲナーゼで分解し、網膜色素上皮細胞で構成された細胞シートを剥離する工程。 - 網膜色素上皮細胞が、ES細胞、iPS細胞又は前駆細胞を分化誘導して得られた細胞である請求項1~5のいずれか1項に記載の製造方法。
- 請求項1~6のいずれか1項に記載の方法で製造された細胞シート。
- 生体外で幹細胞又は前駆細胞を分化誘導して得られた網膜色素上皮細胞で形成された細胞層、当該細胞から分泌された基底膜、及び血管形成細胞層を含む移植用細胞シート。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2882802A CA2882802C (en) | 2012-08-24 | 2013-08-23 | Method for producing retinal pigment epithelial cell sheet |
KR1020157007102A KR102254082B1 (ko) | 2012-08-24 | 2013-08-23 | 망막 색소 상피 세포 시트의 제조 방법 |
US14/423,256 US11033586B2 (en) | 2012-08-24 | 2013-08-23 | Method for producing retinal pigment epithelial cell sheet |
SG11201501319PA SG11201501319PA (en) | 2012-08-24 | 2013-08-23 | Method for producing retinal pigment epithelial cell sheet |
CN201380051245.0A CN104755611A (zh) | 2012-08-24 | 2013-08-23 | 用于生产视网膜色素上皮细胞片层的方法 |
AU2013306720A AU2013306720B2 (en) | 2012-08-24 | 2013-08-23 | Method for producing retinal pigment epithelial cell sheet |
EP13830548.7A EP2889374B1 (en) | 2012-08-24 | 2013-08-23 | Method for producing retinal pigment epithelial cell sheet |
BR112015003839-5A BR112015003839B1 (pt) | 2012-08-24 | 2013-08-23 | Método para produzir lâmina de células do epitélio pigmentar da retina |
JP2014531688A JP6292557B2 (ja) | 2012-08-24 | 2013-08-23 | 網膜色素上皮細胞シートの製造方法 |
ZA2015/01976A ZA201501976B (en) | 2012-08-24 | 2015-03-23 | Method for producing retinal pigment epithelial cell sheet |
HK15111198.0A HK1210496A1 (en) | 2012-08-24 | 2015-11-13 | Method for producing retinal pigment epithelial cell sheet |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012-185932 | 2012-08-24 | ||
JP2012185932 | 2012-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014030749A1 true WO2014030749A1 (ja) | 2014-02-27 |
Family
ID=50150052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/072589 WO2014030749A1 (ja) | 2012-08-24 | 2013-08-23 | 網膜色素上皮細胞シートの製造方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US11033586B2 (ja) |
EP (1) | EP2889374B1 (ja) |
JP (1) | JP6292557B2 (ja) |
KR (1) | KR102254082B1 (ja) |
CN (2) | CN104755611A (ja) |
AU (1) | AU2013306720B2 (ja) |
BR (1) | BR112015003839B1 (ja) |
CA (1) | CA2882802C (ja) |
HK (1) | HK1210496A1 (ja) |
SG (1) | SG11201501319PA (ja) |
WO (1) | WO2014030749A1 (ja) |
ZA (1) | ZA201501976B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015125941A1 (ja) * | 2014-02-21 | 2015-08-27 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
JP2020504625A (ja) * | 2016-11-09 | 2020-02-13 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズThe U.S.A.As Represented By The Secretary,Department Of Health And Human Services | 細胞療法および創薬のための3d血管化ヒト眼組織 |
WO2021014515A1 (ja) | 2019-07-19 | 2021-01-28 | 東京エレクトロン株式会社 | 細胞の分化状態の評価方法 |
JP2021531807A (ja) * | 2018-07-31 | 2021-11-25 | ロキット ヘルスケア インク. | 多層細胞シートの製造方法、及び、これを用いて製造された多層細胞シート |
WO2023210609A1 (ja) * | 2022-04-27 | 2023-11-02 | ファーマバイオ株式会社 | 細胞シート作製方法 |
WO2024116998A1 (ja) * | 2022-11-28 | 2024-06-06 | ニッタ株式会社 | 細胞シート作製装置及び細胞シート作製装置用無菌閉鎖系回路 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2721952C (en) * | 2008-04-22 | 2019-11-12 | Regenerative Research Foundation | Retinal pigment epithelial stem cells |
BR112013021514A2 (pt) | 2011-02-25 | 2020-09-29 | Riken | método de produção de camada de célula epitelial de pigmento retinal |
CN106282096A (zh) * | 2016-10-19 | 2017-01-04 | 江苏艾尔康生物医药科技有限公司 | 一种人类视网膜色素上皮细胞层的分离培养方法 |
AU2017359336B2 (en) | 2016-11-09 | 2023-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tissue clamp and implantation method |
CN109464705B (zh) * | 2018-11-19 | 2021-08-17 | 爱尔眼科医院集团股份有限公司 | 一种rpe细胞片及其应用和制备方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02211865A (ja) | 1989-02-10 | 1990-08-23 | Kao Corp | 細胞培養支持体材料 |
JPH05192138A (ja) | 1992-01-22 | 1993-08-03 | Kao Corp | 皮膚細胞培養法及び培養皮膚 |
JPH09501303A (ja) * | 1993-04-30 | 1997-02-10 | フォトジェネシス インコーポレイテッド | 網膜色素上皮移植 |
JP2005538742A (ja) | 2002-07-25 | 2005-12-22 | ザ・スクリプス・リサーチ・インステイチユート | 造血幹細胞及び該細胞を使用して眼の新生血管の疾患を治療する方法 |
JP2007500509A (ja) | 2003-07-30 | 2007-01-18 | アクセラ, インコーポレイテッド | 長期一次網膜細胞培養およびストレスモデル、ならびにこれらの使用方法 |
JP2007517210A (ja) | 2003-12-24 | 2007-06-28 | ファイザー・プロダクツ・インク | 網膜毒性のスクリーニング法 |
WO2008056779A1 (fr) | 2006-11-09 | 2008-05-15 | Japan As Represented By The President Of International Medical Center Of Japan | Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire |
JP2008220354A (ja) | 2007-03-14 | 2008-09-25 | Cellseed Inc | 細胞表層蛋白修復方法 |
WO2009035217A1 (en) | 2007-09-14 | 2009-03-19 | Chabiotech Co., Ltd. | Process for differentiation of vascular endothelial progenitor cells from embryoid bodies derived from embryonic stem cells using hypoxic media condition |
WO2011142364A1 (ja) | 2010-05-10 | 2011-11-17 | 独立行政法人理化学研究所 | 細胞シート作製方法 |
WO2012115244A1 (ja) * | 2011-02-25 | 2012-08-30 | 独立行政法人理化学研究所 | 網膜色素上皮細胞シートの製造方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2018228C (en) | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Cell culture systems and media |
SG49267A1 (en) * | 1989-08-14 | 1998-05-18 | Photogenesis Inc | Surgical instrument and cell isolation and transplantation |
CA2501226A1 (en) | 2002-10-04 | 2004-04-22 | Tissuetech, Inc | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
SG10201606441SA (en) * | 2004-01-23 | 2016-09-29 | Astellas Inst For Regenerative Medicine | Improved modalities for the treatment of degenerative diseases of the retina |
WO2005079879A1 (ja) | 2004-02-25 | 2005-09-01 | Ihara & Company Ltd. | コラーゲンゲルおよびその製造方法 |
JP2005261292A (ja) * | 2004-03-18 | 2005-09-29 | Ihara Suisan Kk | 細胞シートおよびその製造方法 |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
US7846467B2 (en) * | 2005-01-13 | 2010-12-07 | Minas Theodore Coroneo | Ocular scaffold for stem cell cultivation and methods of use |
GB0806746D0 (en) | 2008-04-14 | 2008-05-14 | Ucl Business Plc | Membrane |
CN101629162B (zh) * | 2009-08-26 | 2011-05-25 | 暨南大学 | 组织工程细胞片及其制备方法 |
ES2963295T3 (es) * | 2010-07-12 | 2024-03-26 | Univ Southern California | Sustrato biocompatible para facilitar las interconexiones entre células madre y tejidos diana y métodos para implantarlo |
CN101940591B (zh) * | 2010-08-27 | 2013-09-18 | 上海士腾生物技术有限公司 | 促血管再生或新生的制剂及其制备方法 |
-
2013
- 2013-08-23 JP JP2014531688A patent/JP6292557B2/ja active Active
- 2013-08-23 CA CA2882802A patent/CA2882802C/en active Active
- 2013-08-23 SG SG11201501319PA patent/SG11201501319PA/en unknown
- 2013-08-23 KR KR1020157007102A patent/KR102254082B1/ko active IP Right Grant
- 2013-08-23 WO PCT/JP2013/072589 patent/WO2014030749A1/ja active Application Filing
- 2013-08-23 EP EP13830548.7A patent/EP2889374B1/en active Active
- 2013-08-23 CN CN201380051245.0A patent/CN104755611A/zh active Pending
- 2013-08-23 CN CN202110371522.2A patent/CN113088481A/zh active Pending
- 2013-08-23 US US14/423,256 patent/US11033586B2/en active Active
- 2013-08-23 AU AU2013306720A patent/AU2013306720B2/en active Active
- 2013-08-23 BR BR112015003839-5A patent/BR112015003839B1/pt active IP Right Grant
-
2015
- 2015-03-23 ZA ZA2015/01976A patent/ZA201501976B/en unknown
- 2015-11-13 HK HK15111198.0A patent/HK1210496A1/xx unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02211865A (ja) | 1989-02-10 | 1990-08-23 | Kao Corp | 細胞培養支持体材料 |
JPH05192138A (ja) | 1992-01-22 | 1993-08-03 | Kao Corp | 皮膚細胞培養法及び培養皮膚 |
JPH09501303A (ja) * | 1993-04-30 | 1997-02-10 | フォトジェネシス インコーポレイテッド | 網膜色素上皮移植 |
JP2005538742A (ja) | 2002-07-25 | 2005-12-22 | ザ・スクリプス・リサーチ・インステイチユート | 造血幹細胞及び該細胞を使用して眼の新生血管の疾患を治療する方法 |
JP2007500509A (ja) | 2003-07-30 | 2007-01-18 | アクセラ, インコーポレイテッド | 長期一次網膜細胞培養およびストレスモデル、ならびにこれらの使用方法 |
JP2007517210A (ja) | 2003-12-24 | 2007-06-28 | ファイザー・プロダクツ・インク | 網膜毒性のスクリーニング法 |
WO2008056779A1 (fr) | 2006-11-09 | 2008-05-15 | Japan As Represented By The President Of International Medical Center Of Japan | Procédé destiné à la culture et au passage d'une cellule souche embryonnaire de primate, et procédé destiné à induire la différenciation de la cellule souche embryonnaire |
JP2008220354A (ja) | 2007-03-14 | 2008-09-25 | Cellseed Inc | 細胞表層蛋白修復方法 |
WO2009035217A1 (en) | 2007-09-14 | 2009-03-19 | Chabiotech Co., Ltd. | Process for differentiation of vascular endothelial progenitor cells from embryoid bodies derived from embryonic stem cells using hypoxic media condition |
WO2011142364A1 (ja) | 2010-05-10 | 2011-11-17 | 独立行政法人理化学研究所 | 細胞シート作製方法 |
WO2012115244A1 (ja) * | 2011-02-25 | 2012-08-30 | 独立行政法人理化学研究所 | 網膜色素上皮細胞シートの製造方法 |
Non-Patent Citations (34)
Title |
---|
"Japan tissue culture conference ed., Technique of Tissue Culture 3rd edition", ASAKURA SHOTEN, pages: 581 |
"METHODS IN ENZYMOLOGY", vol. 121, ACADEMIC PRESS, article "Immunochemical Techniques (Part I: Hybridoma Technology and Monoclonal Antibodies" |
"Methods in ENZYMOLOGY", vol. 70, article "Immunochemical Techniques (Part A)" |
"METHODS IN ENZYMOLOGY", vol. 73, article "Immunochemical Techniques(Part B)" |
"METHODS IN ENZYMOLOGY", vol. 74, article "Immunochemical Techniques (Part C)" |
"METHODS IN ENZYMOLOGY", vol. 84, article "Immunochemical Techniques (Part D: Selected Immunoassays" |
"METHODS IN ENZYMOLOGY", vol. 92, article "Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods" |
ACTA OPHTHALMOL., vol. 89, no. 6, September 2011 (2011-09-01), pages E490 - 5 |
AM J OPHTHALMOL., vol. 153, no. 1, January 2012 (2012-01-01), pages 120 - 7 |
ARVYDAS M, IOVS, vol. 47, 2006, pages 3612 - 3624 |
BR J OPHTHALMOL., vol. 95, no. 3, March 2011 (2011-03-01), pages 370 - 5 |
EIJI ISHIKAWA ET AL.: "Enzyme Immunoassay", 1978, IGAKU-SHOIN |
EIJI ISHIKAWA ET AL.: "Enzyme Immunoassay, 2ND ED.", 1982, IGAKU-SHOIN |
EIJI ISHIKAWA ET AL.: "Enzyme Immunoassay, 3rd ed.", 1987, IGAKU-SHOIN |
HIROSHI IRIE: "cont. Radioimmunoassay", 1979, KODANSHA |
HIROSHI IRIE: "Radioimmunoassay", 1974, KODANSHA |
INVEST OPHTHALMOL VIS SCI., vol. 36, no. 2, February 1995 (1995-02-01), pages 381 - 90 |
INVEST. OPHTHALMOL. VIS. SCI., vol. 36, no. 2, 1995, pages 381 - 390 |
JOURNAL OF CELL SCIENCE, vol. 122, 1 September 2009 (2009-09-01), pages 3169 - 79 |
JPN. J. TRANSPLANT, vol. 44, 2009, pages 231 - 235 |
N ENGL J MED., vol. 348, 2003, pages 593 - 600 |
NAT METHODS., vol. 8, no. 5, May 2011 (2011-05-01), pages 409 - 12 |
NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 101 - 106 |
NATURE PROTOCOLS, vol. 4, no. 5, 2009, pages 662 - 673 |
NEUROSCIENCE LETTERS, vol. 458, 2009, pages 126 - 131 |
NEUROSCIENCE LETTERS, vol. 458, no. 3, 24 July 2009 (2009-07-24), pages 126 - 31 |
PROC. JPN. ACAD., SER. B, vol. 85, 2009, pages 348 - 362 |
SATOSHI OKAMOTO ET AL.: "Karei Ohan Hensei", EXPERIMENTAL MEDICINE, vol. 30, no. 10, 2012, pages 138 - 142, XP008178297 * |
SCIENCE., vol. 275, no. 5302, 14 February 1997 (1997-02-14), pages 964 - 7 |
See also references of EP2889374A4 |
STEM CELLS DEV., vol. 13, no. 3, June 2004 (2004-06-01), pages 229 - 42 |
TADASHI SASAGAWA ET AL.: "Saibo Sheet Sekisoka Soshikinai ni Okeru Kekkan Naihi Saibo Network Keisei ni Kakawaru Bunshi No Tansaku", REGENERATIVE MEDICINE, vol. 11, 2012, pages 250, XP008178096 * |
TAKAHASHI, K. ET AL., CELL, vol. 131, 2007, pages 861 - 872 |
TAKAHASHI, K.; YAMANAKA, S., CELL, vol. 126, 2006, pages 663 - 676 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015125941A1 (ja) * | 2014-02-21 | 2015-08-27 | 株式会社ヘリオス | 眼疾患治療剤、そのスクリーニング方法または網膜色素上皮細胞移植に伴う拒絶反応の予測方法 |
US10240201B2 (en) | 2014-02-21 | 2019-03-26 | Healios K.K. | Eye disease treatment agent, screening method therefor, and method for predicting rejection response associated with retinal pigment epithelial cell transplant |
JP2020504625A (ja) * | 2016-11-09 | 2020-02-13 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズThe U.S.A.As Represented By The Secretary,Department Of Health And Human Services | 細胞療法および創薬のための3d血管化ヒト眼組織 |
US11458225B2 (en) | 2016-11-09 | 2022-10-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 3D vascularized human ocular tissue for cell therapy and drug discovery |
JP7222900B2 (ja) | 2016-11-09 | 2023-02-15 | ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 細胞療法および創薬のための3d血管化ヒト眼組織 |
JP2021531807A (ja) * | 2018-07-31 | 2021-11-25 | ロキット ヘルスケア インク. | 多層細胞シートの製造方法、及び、これを用いて製造された多層細胞シート |
JP7228672B2 (ja) | 2018-07-31 | 2023-02-24 | ロキット ヘルスケア インク. | 多層細胞シートの製造方法、及び、これを用いて製造された多層細胞シート |
WO2021014515A1 (ja) | 2019-07-19 | 2021-01-28 | 東京エレクトロン株式会社 | 細胞の分化状態の評価方法 |
WO2023210609A1 (ja) * | 2022-04-27 | 2023-11-02 | ファーマバイオ株式会社 | 細胞シート作製方法 |
WO2024116998A1 (ja) * | 2022-11-28 | 2024-06-06 | ニッタ株式会社 | 細胞シート作製装置及び細胞シート作製装置用無菌閉鎖系回路 |
Also Published As
Publication number | Publication date |
---|---|
CA2882802C (en) | 2021-07-06 |
EP2889374A4 (en) | 2016-03-30 |
US20150250828A1 (en) | 2015-09-10 |
KR20150047538A (ko) | 2015-05-04 |
KR102254082B1 (ko) | 2021-05-18 |
CN104755611A (zh) | 2015-07-01 |
ZA201501976B (en) | 2018-11-28 |
BR112015003839A2 (pt) | 2017-07-04 |
AU2013306720A1 (en) | 2015-03-26 |
JP6292557B2 (ja) | 2018-03-14 |
CN113088481A (zh) | 2021-07-09 |
EP2889374A1 (en) | 2015-07-01 |
AU2013306720B2 (en) | 2018-10-18 |
CA2882802A1 (en) | 2014-02-27 |
BR112015003839B1 (pt) | 2021-12-28 |
US11033586B2 (en) | 2021-06-15 |
SG11201501319PA (en) | 2015-04-29 |
HK1210496A1 (en) | 2016-04-22 |
JPWO2014030749A1 (ja) | 2016-08-08 |
EP2889374B1 (en) | 2017-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6292557B2 (ja) | 網膜色素上皮細胞シートの製造方法 | |
JP6011979B2 (ja) | 網膜色素上皮細胞シートの製造方法 | |
JP2023126246A (ja) | 血管オルガノイド、オルガノイドの製造及び使用方法 | |
CN111876371A (zh) | 心脏细胞培养材料 | |
JP5867926B2 (ja) | 細胞シート作製方法 | |
JP7274683B2 (ja) | 多能性幹細胞から樹状分岐した集合管を伴う腎臓構造を作製する方法 | |
KR100996846B1 (ko) | 비점막 상피세포를 이용한 각막 또는 결막 조직 시트 | |
AU2022280062A1 (en) | Methods to generate macular, central and peripheral retinal pigment epithelial cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13830548 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014531688 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2882802 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14423256 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013830548 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20157007102 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013306720 Country of ref document: AU Date of ref document: 20130823 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015003839 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015003839 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150223 |